Docosahexaenoic Acid

PubMed ID: 25711158

Microencapsulated fish‑oil powders produced similar plasma/RBC omega‑3 increases as capsules (supports achieving therapeutic blood levels).

PubMed ID: 30197273

OM‑3CA produced a clear triglyceride lowering (~26%) in overweight NAFLD patients—good evidence for improving blood fats.

PubMed ID: 7702027

~9‑month high‑dose fish oil lowered triglycerides by ~19% in CAD patients—robust clinical triglyceride lowering.

PubMed ID: 21233083

DHA in children with NAFLD improved triglycerides along with liver fat—strong metabolic/lipid benefit.

PubMed ID: 23220074

Long‑term DHA produced durable triglyceride improvements in children with NAFLD—consistent healthy‑blood‑fat effect.

PubMed ID: 26026214

DHA produced large hepatic‑fat and concurrent triglyceride reductions in overweight children—robust metabolic improvement.

PubMed ID: 26226139

Fish oil improved total cholesterol and triglycerides in adults with NAFLD and dyslipidemia—meaningful lipid effects.

PubMed ID: 29971527

OM‑3 free‑acid raised plasma DHA and reduced liver fat modestly; triglyceride improvements were noted in some arms—moderate blood‑fat benefit.

PubMed ID: 16384692

Fish-oil and B-vitamin supplementation corrected low erythrocyte DHA/status in schizophrenia patients—direct blood-fat improvement.

PubMed ID: 24675168

Controlled diet (high n-3, low n-6) produced large increases in plasma/phospholipid DHA and EPA and reduced AA across lipid pools.

PubMed ID: 31782377

Isotope feeding demonstrated increased LPC-DHA production with higher choline, clarifying plasma DHA transport and blood-fat status.

PubMed ID: 34130033

Dietary method substantially increased EPA+DHA intake in free‑living adults, demonstrating feasibility to raise n‑3 exposure relevant to blood lipid changes.

PubMed ID: 1971991

Marine EPA+DHA diet lowered triglycerides (~−39%) and systolic BP in a controlled feeding crossover—robust metabolic effects on blood lipids.

PubMed ID: 9310278

Large RCT showed fish oil reduced cardiac events and nonfatal MI; demonstrates clinically meaningful cardiovascular risk reduction consistent with improved blood lipid/clinical outcomes.

PubMed ID: 11528489

Preterm infant study showed substantial retention of supplemented DHA, demonstrating increased tissue/plasma DHA availability.

PubMed ID: 12010583

In hypertriglyceridemic men fish oil greatly lowered fasting and postprandial triglycerides and massively increased platelet EPA/DHA — strong evidence for improving blood lipid profile (with LDL caveat).

PubMed ID: 12663273

Randomized trial: EPA+DHA modestly lowered fasting triglycerides compared with high‑ALA which increased TG—direct lipid benefit evidence.

PubMed ID: 15939062

Fish oil substantially increased EPA/DHA and produced clinically significant TG (-23%) and sdLDL reductions in men with atherogenic profile.

PubMed ID: 16960164

Dietary lowering of n‑6:n‑3 by adding EPA/DHA reduced fasting and postprandial TAG—strong triglyceride lowering evidence.

PubMed ID: 17158408

EPA/DHA addition reduced fasting/postprandial TAG and decreased small dense LDL proportion—favorable lipid profile changes.

PubMed ID: 18779299

Fish oil rapidly increased erythrocyte DHA/EPA (biomarker of n‑3 status), reflecting incorporation relevant to blood‑fat biology, though no plasma inflammation change.

PubMed ID: 18683001

SDA intervention raised omega‑3 index and RBC EPA (biomarker improvement for blood‑fat profile), though DHA unchanged.

PubMed ID: 19261730

Controlled dietary interventions showed DHA reduced triglycerides and increased HDL, and distinct LDL fatty‑acid changes—strong lipid‑profile effects.

PubMed ID: 19933935

Higher serum DHA associated with lower incident atrial fibrillation; while an outcome study, it also implies favorable long‑term blood lipid/vascular milieu.

PubMed ID: 20160750

12‑week oral DHA/ALA supplementation increased erythrocyte ALA, EPA and DHA modestly in GI disease patients (incorporation into membranes).

PubMed ID: 23221573

Dietary oils and FADS genotype influenced ALA conversion to EPA/DPA and altered plasma n‑3s—mechanistic support for blood‑fat changes.

PubMed ID: 22810989

6‑week dietary intervention with EPA or DHA margarine produced very large increases in erythrocyte EPA/DHA and omega‑3 index (strong biomarker effect).

PubMed ID: 23179200

30 g/day flaxseed raised red‑cell n‑3s and lowered n‑6/n‑3 ratio (biomarker improvements) though no added inflammation benefit.

PubMed ID: 23332800

High‑dose n‑3 enriched yogurt over 10 weeks increased plasma/RBC EPA/DHA and significantly decreased triglycerides and raised HDL.

PubMed ID: 23328113

Dietary manipulation produced large increases in erythrocyte EPA/DHA—biomarker basis for blood‑fat effects.

PubMed ID: 25216712

Oil interventions raised erythrocyte EPA (conversion) and produced modest, oil‑dependent lipid changes.

PubMed ID: 25515553

Fish‑oil capsules markedly raised DHA and reduced triglycerides and HbA1c in early T2D/metabolic syndrome—strong favorable lipid effects.

PubMed ID: 27279274

180‑day fish‑oil improved triacylglycerol and other lipid traits in T2D—direct beneficial effects on blood fats.

PubMed ID: 28629180

Daily EPA+DHA (~250 mg/day via food) significantly increased Omega‑3 Index and erythrocyte EPA/DHA.

PubMed ID: 29645359

Fatty fish increased HDL particle size and improved HDL lipid content; camelina reduced IDL concentration—favorable lipoprotein effects.

PubMed ID: 29849178

Dose‑response study in young women showed linear incorporation of plasma EPA and DHA and triglyceride lowering at higher doses.

PubMed ID: 29633621

Consuming omega‑3 enriched eggs lowered triglycerides and BP in healthy young adults—improved blood lipid profile.

PubMed ID: 30900815

EPA+DHA supplementation produced clinically meaningful triglyceride reductions (12–16%) and changed PBMC fatty acid composition.

PubMed ID: 32725293

Two fish portions/week reliably raised serum EPA/DHA and improved n‑6:n‑3 ratio.

PubMed ID: 35144649

6‑month RCT in T2DM: fish oil raised erythrocyte EPA/DHA (omega‑3 index) and lowered triglycerides ≈30% — modern clinical evidence.

PubMed ID: 1328817

Fish oil reduced triglycerides by 26% and reduced platelet aggregation — meaningful blood‑lipid and functional benefits.

PubMed ID: 8502270

Fish oil increased serum n‑3 phospholipids and lowered triglycerides in psoriasis patients (biomarker benefit despite no skin improvement).

PubMed ID: 8694015

Dose‑related rises in plasma DHA/AA and reductions in triacylglycerols in healthy adults — strong biochemical evidence for improved blood‑lipid profile.

PubMed ID: 8729141

Observational comparison found lower total cholesterol associated with habitual lake‑fish (higher DHA) diet.

PubMed ID: 12145002

EPA and DHA lowered triacylglycerol and increased arterial compliance in dyslipidemic adults—strong favorable lipid effect.

PubMed ID: 15159226

12-week RCT with 4 g/day fish oil decreased plasma triglycerides, increased platelet EPA/DHA and improved lipid markers (robust blood-fat improvement).

PubMed ID: 16923694

Maternal cod liver oil lessened pregnancy triacylglycerol rise and preserved HDL, indicating favorable maternal lipid effects.

PubMed ID: 18590592

Dietary DHA (DHA‑enriched pork) increased erythrocyte DHA and produced a greater reduction in serum TAG vs control.

PubMed ID: 21362575

Parenteral fish‑oil lipid in preterm infants significantly increased DHA/EPA and decreased AA in plasma/RBC within one week (direct lipid changes).

PubMed ID: 23260750

IV n‑3 increased plasma EPA/DHA and total n‑3 and decreased AA and n‑6:n‑3 ratio; associated with physiological improvement in critically ill patients.

PubMed ID: 23040588

Higher serum n‑3:n‑6 ratios correlated with less coronary plaque progression — observational support for favorable lipid milieu.

PubMed ID: 23998969

Large RCT in statin‑treated patients: OM3‑FFA (2–4 g/d) significantly and dose‑dependently reduced triglycerides and non‑HDL‑C.

PubMed ID: 24528690

Multinational RCT in severe hypertriglyceridemia: large, dose‑dependent TG reductions and improvements in remnant lipid markers with OM3‑FFA (contains DHA).

PubMed ID: 25185754

6:1 EPA:DHA formulation rapidly corrected omega‑3 deficiency and produced marked TG reductions (~48%) in hypertriglyceridemic cohort.

PubMed ID: 24710321

Baseline plasma fatty acids (including n‑3) associated with lower events in CVD cohort (observational lipid-outcome link).

PubMed ID: 27637335

Parenteral fish oil rapidly raised EPA/DHA and improved AA/(EPA+DHA) ratio in septic patients.

PubMed ID: 27919362

OM3‑CA reduced apoCIII and favorably altered lipoprotein subspecies and raised EPA/DHA—strong lipid effect.

PubMed ID: 28410617

High‑dose EPA/DHA markedly increased blood n‑3 levels in atherosclerotic/diabetic patients though clinical clotting/endpoints were largely unchanged.

PubMed ID: 29566189

Maternal/child fish‑oil raised blood n‑3 LC‑PUFA and decreased AA:(DHA+EPA) ratio—clear blood‑fat effects.

PubMed ID: 29471285

48 weeks of DHA in HIV patients produced large early TG reduction and altered fatty‑acid profile.

PubMed ID: 30414540

12 months of seaweed‑DHA produced marked incorporation into multiple plasma lipid classes.

PubMed ID: 29679529

Enteral milk DHA strongly drove serum DHA; parenteral fish oil raised DHA/EPA—clear neonatal blood‑fat effects.

PubMed ID: 29362766

CR±fish oil altered metabolic syndrome parameters and RBC FA ratios (mixed effects).

PubMed ID: 30518052

Large pregnancy RCT: DHA+EPA rose substantially and n‑6/n‑3 ratio decreased (attenuated in obesity).

PubMed ID: 33041091

AMI study showed reductions in triglycerides, apoB and large drop in Lp(a) alongside increased DHA/EPA oxylipins (strong lipid improvements).

PubMed ID: 33266447

Fortified milk raised ω‑3 index by ~30% and lowered homocysteine—meaningful improvements in blood‑lipid/vascular risk biomarkers.

PubMed ID: 37120902

Parenteral vs enteral lipid exposures in preterms altered serum phospholipid AA/DHA trajectories—directly about circulating lipid composition.

PubMed ID: 36706088

High % re‑esterified TG fish oil produced greater erythrocyte EPA and DHA incorporation—direct biomarker improvement of omega‑3 status (omega‑3 index).

PubMed ID: 40598717

Omega‑3 enriched parenteral nutrition raised plasma EPA/DHA concentrations in surgical patients—clinical demonstration of blood‑lipid change.

PubMed ID: 27578110

DHA‑enriched fish oil lowered triglycerides and waist circumference in T2DM (8‑week RCT).

PubMed ID: 17825687

Large RCT: prescription omega‑3 added to simvastatin significantly improved non‑HDL‑C and triglycerides (clinically meaningful lipid changes).

PubMed ID: 20797476

Oily fish intervention raised serum EPA/DHA and improved triglycerides and HDL in dyslipidemic men.

PubMed ID: 23025273

Dietary intervention raising erythrocyte DHA modestly lowered total and LDL cholesterol in a 90‑day RCT.

PubMed ID: 1466329

Fish oil reduced triglycerides by ~36% in heart transplant patients — clinically meaningful TG lowering.

PubMed ID: 1563884

Post‑angioplasty trial: 3 g/day fish oil reduced triglycerides though no restenosis benefit.

PubMed ID: 29223557

High‑quality RCT: addition of 4 g/day ω‑3 to rosuvastatin produced large, clinically meaningful reductions in triglycerides and non‑HDL cholesterol.

PubMed ID: 38056242

EPA+DHA added to statin therapy significantly lowered triglycerides (~−13.6%) though did not affect CAC progression.

PubMed ID: 23522799

n‑3 reduced triglycerides in metabolic syndrome group over 6 weeks — practical improvement in blood fats.

PubMed ID: 32127335

DHA+EPA decreased triglycerides and raised HDL in 16‑week RCT (biomarker improvements).

PubMed ID: 9101424

Marked incorporation of EPA/DHA into serum PCs and ≈26% triglyceride reduction in severe hypertriglyceridemia.

PubMed ID: 2141757

Dose‑dependent incorporation of EPA/DHA with clear, reproducible triglyceride reductions — strong evidence for improving blood fats.

PubMed ID: 2209315

Clear and significant triglyceride lowering in NIDDM with MaxEPA; robust lipid benefit.

PubMed ID: 2195704

Concentrated EPA+DHA produced ~19.5% median triglyceride reduction in hyperlipidemic patients.

PubMed ID: 1831755

Dose‑responsive TG lowering in coronary patients (robust triglyceride effect).

PubMed ID: 1534256

Large trial: triglycerides −21% and modest HDL rise—clear lipid benefit.

PubMed ID: 7939369

Six months post‑bypass EPA+DHA produced ~33% triglyceride lowering and modest insulin effects — robust lipid benefit.

PubMed ID: 8021472

High‑dose fish oil raised HDL2 over 6 months (sex‑specific), a favorable change in lipoprotein subfractions.

PubMed ID: 7486485

4 g/d EPA+DHA for 16 weeks reduced triglycerides (−0.28 mmol/L vs control) in hypertensive adults—clinically relevant lipid effect.

PubMed ID: 7891046

High-EPA/DHA concentrate produced a 28% triglyceride reduction and lowered blood pressure — strong lipid benefit.

PubMed ID: 8933125

Moderate fish/fish‑oil or pure DHA intake reduced fasting and postprandial TG and markedly increased HDL2/HDL3 ratio in healthy men.

PubMed ID: 8729093

Study distinguished EPA as main TG‑lowering agent while DHA influenced HDL subfractions — informative for interpreting lipid effects.

PubMed ID: 10189324

Modest slowing of coronary atherosclerosis may reflect favorable lipid/inflammatory changes over 2 years.

PubMed ID: 10235439

n‑3 lowered platelet counts and affected PAI in combined hyperlipidaemia; relevant to blood profile changes in dyslipidaemia.

PubMed ID: 10799369

DHA and EPA both lowered triglycerides; DHA altered LDL/HDL subfractions beneficially in mildly hyperlipidemic men.

PubMed ID: 10919932

Postmenopausal women given fish oil had large TG drops (−26%) and improved TG:HDL ratio — clear lipid improvement.

PubMed ID: 10938022

Strong reductions in fasting (−35%) and postprandial triglycerides and reduced small dense LDL in men with an atherogenic profile.

PubMed ID: 11303007

Omacor significantly and sustainably lowered triglycerides and VLDL in statin‑treated CHD patients (clinically meaningful lipid benefit).

PubMed ID: 11383326

Low-dose omega-3 added to statin led to increased HDL and reduced triglyceride-related markers (modest lipid benefits).

PubMed ID: 12399272

EPA/DHA lowered TGs and raised HDL2 in T2DM with HTN, though fasting glucose increased — lipid benefits present.

PubMed ID: 12562865

EPA/DHA accelerated postprandial TG clearance, reduced apoB‑48/100 and increased LPL activity—clear beneficial lipid effects.

PubMed ID: 14639800

DHA-enriched eggs lowered triglycerides (~12%) and raised HDL compared with regular eggs (clinically meaningful).

PubMed ID: 12499320

EPA+DHA-containing supplements lowered triglycerides and reduced LDL in one test group—favorable blood-fat changes.

PubMed ID: 15469651

High-dose DHA significantly lowered triglycerides and strongly changed plasma phospholipid composition—direct, robust lipid benefit.

PubMed ID: 15113713

DHA lowered TG (~20%), raised HDL and improved TG:HDL ratio—clear favorable lipid profile changes.

PubMed ID: 15656713

Krill oil improved total cholesterol, triglycerides and LDL versus fish oil and placebo over three months — supports beneficial lipid changes.

PubMed ID: 16296399

Microalgal DHA nearly doubled RBC DHA and raised omega‑3 index from low to desirable levels—strong biomarker improvement.

PubMed ID: 15930485

DHA lowered TGs and small dense LDL fraction but modestly raised LDL/total cholesterol — net mixed but notable effects on blood fats.

PubMed ID: 16806871

Higher-concentration omega-3 formulations showed greater EPA/DHA incorporation and larger short-term triglyceride/VLDL reductions.

PubMed ID: 17229894

Randomized CAD/triglyceride study: DHA (and DHA+EPA) produced substantial ~19–22% triglyceride reductions with many reaching target TG levels.

PubMed ID: 16571158

DHA (0.94 g/day) in vegetarians lowered TG by ~23% (robust RCT) but increased LDL, indicating a strong TG effect with mixed lipid profile impact.

PubMed ID: 17684201

3 g/day DHA substantially lowered TG and large VLDL and reduced small dense LDL (though LDL‑C rose modestly) — robust triglyceride benefit.

PubMed ID: 17977469

Dose‑response RCT: DHA produced dose‑dependent, large triglyceride reductions and clear rises in erythrocyte DHA — strong lipid effects.

PubMed ID: 17393216

High‑dose DHA added to statin therapy produced major triglyceride reductions and further cholesterol lowering in hypertriglyceridemic patients.

PubMed ID: 17179770

Large RCT in HIV patients: n‑3 PUFA produced ≈25% median TG reduction—robust triglyceride lowering.

PubMed ID: 17199721

Long‑chain n‑3 raised plasma EPA/DHA, lowered TG and reduced CRP/IL‑6 (crossover trial).

PubMed ID: 18490931

Adding oily fish or fish oil during weight loss modestly but consistently lowered triglycerides and favorably affected cholesterol measures.

PubMed ID: 19084376

Milk fortified with fish oil/vitamins reduced TAG and improved HDL/LDL, though additional nutrients confound attribution to DHA alone.

PubMed ID: 18491071

Fish oil supplementation during calorie restriction independently improved fasting insulin/HOMA‑IR and contributed to triglyceride lowering.

PubMed ID: 19573960

n‑3 enriched enteral feeding in elderly patients incorporated EPA/DHA into plasma lipids and lowered triglycerides after 3 months.

PubMed ID: 19685375

Omacor reduced plasma triglycerides in ART‑treated HIV patients (significant metabolic benefit).

PubMed ID: 19915202

Marked reduction in plasma n‑6/n‑3 ratio after 4 weeks of EPA+DHA (favorable lipid composition change).

PubMed ID: 20877395

Adding omega‑3 to simvastatin produced a very large additional triglyceride reduction (41% vs 13.9%), strong evidence for improving blood lipids.

PubMed ID: 21178084

2 g/day algal DHA lowered triglycerides and shifted VLDL/LDL/HDL particle sizes favorably in overweight/obese adults (small RCT with meaningful lipid changes).

PubMed ID: 20803425

Low‑dose fish oil modestly prevented serum TG increase in elderly — clinically meaningful albeit small.

PubMed ID: 20420756

Daily beverage with 200 mg EPA + 300 mg DHA substantially raised the n‑3 index in low‑status subjects over 8 weeks (robust biomarker improvement linked to blood‑fat profile).

PubMed ID: 22212377

4 g/day EPA+DHA significantly lowered triglycerides in HAART-treated HIV patients — strong blood‑fat benefit.

PubMed ID: 21862301

Re-esterified omega-3 (rTAG) lowered fasting triglycerides over 6 months in statin-treated dyslipidemic patients—formulation-specific evidence for TG lowering.

PubMed ID: 22108152

Prescription omega-3 added to atorvastatin favorably shifted LDL subfractions to larger particles and lowered proatherogenic markers—meaningful blood-fat remodeling.

PubMed ID: 21924882

4 g/day EPA+DHA produced marked triglyceride reductions (−26%) in hypertriglyceridemic adults—strong direct evidence for improving blood fats.

PubMed ID: 21297494

Prescription EPA+DHA lowered TG and VLDL in primary hypercholesterolemia (with a small LDL rise)—solid triglyceride-lowering evidence.

PubMed ID: 22932281

Dose‑dependent, well‑characterized increases of EPA/DHA across plasma, RBC and platelets with fish intake show robust biochemical changes in blood lipid pools (large controlled trial).

PubMed ID: 22892157

Prescription omega‑3 and combinations produced meaningful triglyceride reductions (clinical metabolic syndrome trial).

PubMed ID: 22653220

JELIS analysis: changes in plasma DHA correlated modestly with LDL‑C changes (large dataset, associative evidence).

PubMed ID: 22929118

Substantial increases in RBC omega‑3 index and trends toward triglyceride lowering after 12 weeks; strong biomarker changes.

PubMed ID: 22669332

Lovaza in postmenopausal women increased n‑3 status, lowered triglycerides and raised HDL (direct lipid improvements).

PubMed ID: 23238663

In hypertensive/diabetic patients fish oil increased platelet EPA/DHA and lowered triglycerides and oxidative stress—favorable blood lipid effects.

PubMed ID: 23817470

In healthy young adults DHA substantially lowered fasting triglycerides (~28%) and raised RBC DHA—strong triglyceride-lowering evidence.

PubMed ID: 24252845

Well‑powered dose‑response RCT showing predictable, dose‑dependent increases in the RBC omega‑3 index (quantitative biomarker improvement of blood fatty acid profile).

PubMed ID: 23725919

Large randomized trial in mild hypertriglyceridemia: combined EPA+DHA 4 g/day produced substantially larger triglyceride reductions vs EPA alone (clear clinical lipid benefit).

PubMed ID: 24314359

One‑year randomized data confirmed sustained and dose‑dependent triglyceride lowering with combined EPA+DHA (4 g/day)—robust long‑term lipid benefit.

PubMed ID: 24299019

Controlled metabolic study: 4 g/day ω‑3 ethyl esters added to atorvastatin markedly lowered VLDL‑TG via reduced production and increased clearance—strong TG evidence.

PubMed ID: 24228803

Pilot in children with primary hyperlipidemia: DHA showed favorable HDL↑ and TG↓ signals (preliminary but promising).

PubMed ID: 24259553

Responder analysis: high erythrocyte EPA responders had larger decreases in plasma TG and VLDL metrics—supports TG benefit in responders.

PubMed ID: 24067797

EPA/DHA liquid diet lowered apoB and improved glycemic markers in elderly diabetics—favorable lipid/metabolic signals.

PubMed ID: 24461313

12‑week krill oil reduced fasting triglycerides by ≈10% without raising LDL‑C—clinically meaningful TG lowering.

PubMed ID: 24829493

DHA‑enriched canola oil produced large TG reductions (~−20%) and increased HDL, with meaningful predicted CHD risk reduction in a well‑controlled crossover trial.

PubMed ID: 24830830

High‑dose fish oil increased RBC EPA and the LC n‑3 index substantially; DHA incorporation was variable—biomarker support for blood‑fat modulation potential.

PubMed ID: 25122648

Dose‑dependent triglyceride lowering from low‑dose EPA+DHA observed in a large RCT (in a plant‑sterol matrix).

PubMed ID: 25406967

Both microencapsulated powder and liquid meals doubled blood EPA and raised DHA—clear blood‑lipid (fatty‑acid) status improvement.

PubMed ID: 25123060

Microalgal DHA+EPA lowered triglycerides by ~19% vs control in a double‑blind randomized trial—clinically relevant lipid benefit.

PubMed ID: 24553695

Echium oil markedly raised EPA/DPA and produced lipid changes including TG reduction (blood‑fat modulation).

PubMed ID: 26328782

Matched‑dose fish oil and krill oil produced similar plasma and RBC EPA/DHA increases (bioavailability relevant to blood‑fat effects).

PubMed ID: 26620373

DHA‑enriched canola oil reduced PCSK9 and triglycerides and altered cholesterol markers (mechanistic blood‑fat benefits).

PubMed ID: 26328624

In statin-treated high-risk patients, omega‑3 carboxylic acids significantly lowered triglycerides, increased LDL particle size and reduced Apo CIII—clear favorable lipid profile changes.

PubMed ID: 26222126

TAK‑085 (EPA+DHA) produced robust reductions in small dense LDL and increased LDL particle size (strong blood‑fat improvement).

PubMed ID: 26247967

RBC DPA inversely associated with triglycerides at baseline and increased dose‑dependently with supplementation (strong lipid biomarker relationships).

PubMed ID: 26019023

Adding EPA+DHA to plant‑sterol spread reduced large VLDL TG/Chol and shifted HDL subclass lipids (beneficial lipid subclass changes).

PubMed ID: 26697137

Enteral EPA/DHA in frail elderly lowered plasma triglycerides while increasing RBC n‑3—evidence of favorable lipid effects in a clinical feeding trial.

PubMed ID: 27084093

Higher whole-blood DHA in schoolchildren was associated with lower triglycerides and better insulin resistance measures—observational evidence linking DHA status to healthier blood lipids.

PubMed ID: 26262712

Fish oil plus vitamin E lowered total and LDL cholesterol in dyslipidemic menopausal women (lipid lowering with combination therapy).

PubMed ID: 27733252

DHA lowered postprandial triglycerides (−20%) though raised LDL‑C (mixed but clear TG benefit).

PubMed ID: 27281302

DHA increased HDL, raised adiponectin and reduced IL‑18; produced differential favorable changes in several lipid/inflammatory markers.

PubMed ID: 27913872

4 g/day fish oil lowered triglycerides and raised HDL in type 2 diabetes with abdominal obesity—meaningful improvements in blood lipid profile.

PubMed ID: 27721230

Omega‑3 in hemodialysis patients decreased triglycerides and total cholesterol—supporting lipid benefits in this population.

PubMed ID: 27600795

Ethyl‑ester omega‑3 (2–4 g/day) produced robust, dose-expected ~30% triglyceride reductions in hypertriglyceridemic patients—strong, consistent evidence for improving blood lipids.

PubMed ID: 28063515

Fish oil increased adiponectin and subgroup analyses showed lipid and glucose improvements mediated by adiponectin increases—supportive mechanism for lipid benefits.

PubMed ID: 28457318

One month high‑dose fish oil markedly increased RBC omega‑3 index (EPA+DHA) — biomarker consistent with improved blood lipid profile.

PubMed ID: 27404516

Fish‑oil in T2D markedly increased erythrocyte EPA/DHA and CMPF; CMPF correlated with lower triglycerides.

PubMed ID: 28515020

DHA increased RBC Omega‑3 Index more than equivalent EPA—strong evidence DHA raises systemic omega‑3 status.

PubMed ID: 29246960

High‑dose EPA+DHA significantly lowered triglycerides and was associated with attenuation of coronary fibrous plaque progression.

PubMed ID: 28710178

Lovaza (EPA+DHA) markedly reduced triglycerides and prevented worsening albuminuria in diabetics—clear metabolic lipid benefits.

PubMed ID: 28648475

DHA produced large, rapid and sustained triglyceride reductions in ART‑treated HIV patients (strong lipid‑lowering effect).

PubMed ID: 28112528

Omega‑3 lowered LDL and hs‑CRP in men with CAD over 8 weeks—beneficial lipid and inflammatory effects.

PubMed ID: 30297663

Dose‑response RCT in premenopausal women: low‑dose DHA substantially lowered triglycerides (~−23%) and VLDL‑TG—strong evidence for improving blood lipids.

PubMed ID: 29713249

T2D RCT showed significant triglyceride reductions (~17% within group and ~26% vs placebo) supporting blood‑fat benefits.

PubMed ID: 30227610

Omega‑3 in dialysis patients reduced triglycerides (~−17%) alongside heart rate reductions—clinically relevant lipid improvement.

PubMed ID: 29846653

DHA vs EPA trial documented clinically meaningful LDL‑C increase but favorable LDL particle enlargement and increased LDL turnover — important lipid phenotype effects.

PubMed ID: 30407633

Well‑controlled feeding trial showed DHA reduced triglycerides by ~24% in metabolic‑syndrome subjects — strong evidence for improving blood‑lipid profile.

PubMed ID: 30127297

High‑concentrate EPA+DHA robustly increased RBC ω‑3 and produced triglyceride lowering and liver‑fat improvements in NAFLD subgroup.

PubMed ID: 31535138

DHA (∼3 g/d) substantially lowered triglycerides (~23.5%) and increased LPL activity in healthy adults.

PubMed ID: 31204771

Isotope tracing showed substantial conversion of EPA→DHA and clear metabolic effects on plasma EPA/DHA, informing ω‑3 blood‑fat biology.

PubMed ID: 31595295

Increased oily‑fish intake in children modestly lowered triglycerides and raised HDL with objective RBC EPA+DHA uptake.

PubMed ID: 31271554

High‑dose EPA+DHA (3 g/day) in obese youth produced marked triglyceride reduction (~39%) — large, clinically meaningful lipid effect.

PubMed ID: 30854986

Crossover trial found DHA lowered triglycerides in a larger fraction of individuals than EPA—direct lipid‑lowering evidence.

PubMed ID: 33015732

Two portions/week salmon increased omega‑3 index and produced modest triglyceride reduction — practical dietary lipid improvement.

PubMed ID: 32325778

Combined ω‑3 + vitamin D supplement robustly raised circulating EPA/DHA levels — strong biomarker evidence for improved blood ω‑3 status.

PubMed ID: 32178279

Both EPA‑ and DHA‑rich oils lowered triglycerides ~14% in healthy adults; DHA also caused small LDL/HDL particle shifts.

PubMed ID: 32732154

Omega‑3 supplementation raised omega‑3 index and decreased triglycerides in predialysis CKD patients—clear improvement in blood fats.

PubMed ID: 31963702

Microencapsulated DHA in toddler formula increased whole‑blood DHA and Omega‑3 Index substantially versus non‑encapsulated oil.

PubMed ID: 33227646

Prenatal DHA supplementation raised maternal DHA though no long‑term cognitive benefits were found — clear blood biomarker change.

PubMed ID: 32200533

4 g/day omega‑3 produced marked reductions in fasting and postprandial triglycerides and some favorable lipid changes in statin‑treated dyslipidemic patients.

PubMed ID: 32585854

EPA‑rich microalgae raised omega‑3 index and reduced total and VLDL cholesterol in healthy adults — clear lipid benefits.

PubMed ID: 32188593

EPA+DHA lowered hepatic DNL and increased fat oxidation — mechanistically consistent with improving blood lipid profile.

PubMed ID: 34371898

Mediterranean diet increased whole‑blood EPA+DHA and improved n‑6/n‑3 ratio in coronary patients — dietary route to healthier blood fats.

PubMed ID: 34552200

800 mg/day prenatal DHA markedly increased maternal RBC‑DHA and maternal–infant DHA equilibrium — strong blood DHA increase.

PubMed ID: 34371972

DHA‑rich supplementation in overweight postmenopausal women reduced triglycerides significantly relative to control.

PubMed ID: 34684525

Eating salmon for 8 weeks lowered triglycerides modestly in overweight adults.

PubMed ID: 33684737

EPA+DHA reduced metabolic‑syndrome frequency and fasting glucose, improving cardiometabolic/lipid‑related outcomes.

PubMed ID: 33933722

High‑dose EPA+DHA in abdominally obese adults markedly reduced VLDL particle counts and triglycerides (very strong lipoprotein effect).

PubMed ID: 34989797

Large double‑blind RCT of krill‑derived omega‑3 produced significant triglyceride lowering and raised plasma EPA+DHA (strong lipid outcome evidence).

PubMed ID: 36409163

Blue mussel lipid extract reduced triglycerides and improved insulin/TNF markers (beneficial effects on blood lipids/inflammation).

PubMed ID: 36050695

Robust RCT: 4 g/day EPA+DHA added to statin therapy produced large TG reductions, lowered non‑HDL and markedly reduced small dense LDL—strong lipid benefits.

PubMed ID: 36571774

Fish‑oil improved triglycerides and HDL in older adults along with muscle/function gains—supportive cardiometabolic lipid effects.

PubMed ID: 37681568

EPA+DHA associated with triglyceride reductions that correlated with coronary fatty plaque regression.

PubMed ID: 36728325

Dose‑response DHA study robustly raised RBC/Omega‑3 Index in a dose‑dependent manner; reached cardioprotective targets.

PubMed ID: 38001474

EPA/DHA added to glimepiride improved triglycerides and raised HDL in T2D over 12 weeks — good supportive evidence.

PubMed ID: 38256336

High‑dose EPA+DHA lowered remnant‑like lipoprotein cholesterol in dialysis patients — relevant to atherogenic blood fats.

PubMed ID: 37532570

Self‑emulsifying EPA raised plasma EPA and EPA‑derived anti‑inflammatory metabolites rapidly and dose‑dependently.

PubMed ID: 39163858

4 g/day fish oil produced a large clinically meaningful triglyceride reduction and lipidomic changes.

PubMed ID: 38830807

Omega‑3 ethyl esters significantly lowered triglycerides, non‑HDL, VLDL‑C and Apo C‑III in severe hypertriglyceridemia — strong lipid‑lowering evidence.

PubMed ID: 39168625

Scallop oil reduced TG and oxidized‑LDL in higher‑TG subgroup — modest supportive data.

PubMed ID: 38732508

Controlled dietary intervention including fish oil improved triglycerides, LDL and glycemic markers in metabolic risk groups.

PubMed ID: 39770887

Erythrocyte EPA/DHA and n‑3 index rose substantially in the fish‑oil group, consistent with improved blood lipid profile.

PubMed ID: 41082976

Two fish portions/week or EPA+DHA supplement raised omega‑3 index by ≈2 percentage points—robust change in blood fats.

PubMed ID: 40288580

High‑dose EPA+DHA for 12 months raised tissue ω‑3 and lowered plasma triglycerides (dose‑dependent, clinically relevant TG reduction).

PubMed ID: 11303007

Omacor added to simvastatin produced sustained 20–30% triglyceride reductions in CHD patients — clinically meaningful heart‑risk improvement.

PubMed ID: 11837985

Large randomized trial: 1 g/day n‑3 PUFA after MI reduced overall and cardiovascular mortality (robust clinical heart benefit).

PubMed ID: 11207085

Omega-3 prevented post-transplant systolic BP rise and preserved renal function—cardiovascularly relevant in high-risk patients.

PubMed ID: 12075272

Peri-procedural and continued omega-3 therapy reduced angiographic restenosis after angioplasty (clinically relevant cardiac outcome).

PubMed ID: 15469651

DHA lowered triglycerides significantly compared with control—important heart-risk improvement.

PubMed ID: 15113713

DHA lowered TG, raised HDL and reduced resting heart rate in postmenopausal women—favorable heart-risk markers.

PubMed ID: 16806871

Dose/concentration trial showed higher-concentration omega-3 led to greater EPA/DHA incorporation and larger short-term TG/VLDL reductions.

PubMed ID: 17229894

Randomized CAD trial: DHA (±EPA) produced clinically meaningful triglyceride reductions in patients with CAD and high TGs.

PubMed ID: 17374663

Low‑dose DHA raised erythrocyte DHA and modestly lowered diastolic blood pressure — favorable for cardiovascular risk.

PubMed ID: 17393216

High‑dose DHA‑rich fish oil added to statins substantially lowered triglycerides and further reduced cholesterol — direct cardiometabolic benefit.

PubMed ID: 17237316

Fortified dairy drink (including DHA) plus rehab lowered total/LDL cholesterol and hs‑CRP after MI — supportive of post‑MI heart recovery.

PubMed ID: 17875549

In lupus patients fish oil improved endothelial function (FMD) and disease activity—cardiovascular biomarker benefit.

PubMed ID: 17179770

n‑3 PUFA substantially lowered elevated triglycerides in HIV patients on ART—cardiometabolic benefit.

PubMed ID: 18339222

DHA‑rich oil improved heart‑rate variability and lowered resting/submaximal exercise HR in overweight adults.

PubMed ID: 18490931

Fish oil or oily fish modestly lowered triglycerides during weight loss, favorable for cardiovascular risk profile.

PubMed ID: 18982439

Idiopathic dilated cardiomyopathy trial improved multiple arrhythmic risk markers and lowered catecholamines/cytokines—strong cardiac benefit.

PubMed ID: 19084376

Milk fortified with fish oil and vitamins improved HDL and lowered TAG/LDL, but multiple nutrients confound DHA's specific role.

PubMed ID: 18491071

Fish oil improved insulin resistance (HOMA‑IR) and reduced TG during calorie restriction—metabolic heart risk improvements.

PubMed ID: 19573960

Enteral n‑3 feeding in elderly lowered TAG and incorporated EPA/DHA, supporting cardiovascular risk reduction.

PubMed ID: 19515734

PBMC gene changes were anti‑atherogenic/anti‑inflammatory, supporting cardiovascular risk biology.

PubMed ID: 19593941

6‑month fish oil in metabolic syndrome lowered weight, systolic BP and lipids (non‑placebo control), indicating cardiometabolic benefit.

PubMed ID: 19487105

Salmon or fish oil during weight loss produced modest but significant diastolic BP reductions in overweight adults (randomized dietary trial).

PubMed ID: 20542512

Pre‑surgical n‑3 increased plaque EPA and was associated with less plaque inflammation and fewer foam cells (plaque‑stabilizing biology).

PubMed ID: 20877395

Adding omega‑3 to simvastatin produced a much larger triglyceride drop than statin alone (large clinically relevant lipid effect pertinent to CV risk).

PubMed ID: 21178084

2 g/day algal DHA improved lipoprotein particle sizes and lowered triglycerides in overweight/obese adults (small RCT showing favorable cardiometabolic shifts).

PubMed ID: 20071644

Attenuation of meal-induced FMD drop and improved microvascular reactivity indicate vascular cardioprotective effects.

PubMed ID: 20472253

Adolescents had significant SBP/DBP reductions and RBC EPA/DHA increases—clinically relevant heart-supporting effects.

PubMed ID: 22212377

Meaningful triglyceride reductions in HAART-associated hypertriglyceridemia support cardiac risk reduction.

PubMed ID: 21757663

Higher serum DHA was associated with lower carotid IMT in middle-aged men—observational support for vascular benefit.

PubMed ID: 22108152

Adding prescription omega-3 to atorvastatin shifted LDL toward larger, less atherogenic particles and reduced ApoCIII and Lp-PLA2—favorable cardiac risk marker changes.

PubMed ID: 21924882

In hypertriglyceridemic adults, EPA+DHA markedly lowered triglycerides (heart risk factor) though it modestly increased LDL-C—mixed but strong lipid effect relevant to heart support.

PubMed ID: 21297494

Prescription EPA+DHA reduced TG/VLDL in hypercholesterolemia with a small LDL rise—favorable TG effects for cardiovascular risk management.

PubMed ID: 21831993

DHA‑rich NEFA improved postprandial endothelial function (FMD) acutely — a direct vascular mechanism relevant to heart health (well‑powered crossover human study).

PubMed ID: 22892157

Omega‑3 (prescription) reduced triglycerides and, combined with niacin, produced additive lipid and arterial stiffness benefits in metabolic syndrome (clinical trial supporting CV risk factor improvement).

PubMed ID: 23104856

Small randomized pilot showed clinically meaningful systolic and pulse pressure reductions after 6 weeks of fish oil including DHA.

PubMed ID: 22669332

Lovaza raised n‑3 status and lowered triglycerides while raising HDL in postmenopausal women (favorable lipid changes for heart health).

PubMed ID: 23238663

In hypertensive/diabetic patients fish oil reduced platelet oxidative stress and ROS production and lowered triglycerides—cardio-relevant improvements.

PubMed ID: 23817470

Healthy adults: DHA substantially lowered fasting triglycerides (~28%) and modestly lowered BP in men—favorable cardiovascular risk changes.

PubMed ID: 23390192

Randomized trial showed DHA and EPA lowered platelet aggregation (sex‑specific effects), which is cardioprotective via reduced thrombotic tendency.

PubMed ID: 23916928

Large RCT (n‑3 + vitamins) markedly reduced post‑op atrial fibrillation (large effect) though effect is confounded by added antioxidants.

PubMed ID: 24043256

In T2DM patients adding omega‑3 improved diastolic function (mainly in men), a direct measure of cardiac function benefit.

PubMed ID: 23725919

Combined EPA+DHA at 4 g/day produced clinically meaningful triglyceride lowering vs EPA alone—lipid improvements that reduce cardiovascular risk.

PubMed ID: 24314359

One‑year data confirmed sustained triglyceride reductions with combined EPA+DHA (4 g/day), supporting long‑term heart‑risk factor improvement.

PubMed ID: 24299019

ω‑3 ethyl esters added to atorvastatin further reduced VLDL‑TG via lower production and higher clearance—clear beneficial blood‑lipid/heart risk mechanism.

PubMed ID: 24461313

12‑week krill oil lowered fasting triglycerides ≈10% without raising LDL‑C—relevant to cardiovascular risk factors.

PubMed ID: 23351824

In chronic heart failure patients, supplementation substantially raised circulating EPA/DHA and associated with reduced inflammatory marker (pentraxin‑3), relevant to heart disease.

PubMed ID: 24829493

DHA‑enriched canola oil raised HDL, lowered triglycerides and systolic BP and reduced predicted 10‑yr CHD risk in a controlled crossover trial.

PubMed ID: 25122648

Low‑dose EPA+DHA in a plant‑sterol food matrix produced dose‑dependent triglyceride reductions in a large RCT.

PubMed ID: 25123060

Microalgal DHA+EPA significantly lowered triglycerides (~19%) comparable to fish oil—a relevant cardiometabolic benefit.

PubMed ID: 24410834

Lower serum DHA was independently associated with coronary atheroma progression in statin‑treated diabetics—supports DHA relevance to coronary disease progression.

PubMed ID: 24526821

High-dose omega-3 (including DHA) improved subclinical myocardial systolic function in Rett syndrome (RCT, 1 yr).

PubMed ID: 25431880

Salmon consumption increased HRV and lowered HR—objective heart‑supportive effects.

PubMed ID: 24746829

Dose‑related improvement in small‑artery endothelial function and reductions in inflammatory/CV markers support vascular/heart benefit.

PubMed ID: 25565485

High‑dose fish oil lowered central aortic pressure (aortic stiffness) in one arm—favorable cardiovascular effect.

PubMed ID: 26229448

Pre‑op nutraceutical including DHA reduced carotid plaque lipid/cholesterol and fewer perioperative neurologic events (atherothrombotic relevance).

PubMed ID: 26328624

In statin-treated high-risk patients, high-dose omega-3 reduced triglycerides, shifted LDL to larger particles and lowered Apo CIII—changes relevant to cardiovascular risk.

PubMed ID: 26222126

TAK‑085 (EPA+DHA) shifted LDL to larger, less atherogenic particles (favourable cardiometabolic profile).

PubMed ID: 27281302

DHA increased HDL and adiponectin and modulated LDL/TG differently than EPA—favorable CV biomarker changes.

PubMed ID: 27913872

4 g/day fish oil lowered triglycerides and raised HDL in type 2 diabetic patients with abdominal obesity—favorable lipid changes for heart health.

PubMed ID: 27600795

Prescription ethyl‑ester omega‑3 produced substantial (~30%) triglyceride reductions in hypertriglyceridemic patients—clear lipid benefit relevant to cardiac risk.

PubMed ID: 27404516

In T2D, fish‑oil markedly raised EPA/DHA and CMPF; CMPF increase correlated with lower triglycerides (favourable lipid effects).

PubMed ID: 29246960

High‑dose EPA+DHA added to statin therapy reduced triglycerides and attenuated progression of fibrous coronary plaque (per‑protocol), indicating cardiovascular benefit.

PubMed ID: 28648475

DHA produced large, rapid triglyceride reductions in ART‑treated HIV patients—favorable cardiovascular risk factor effect.

PubMed ID: 28112528

Omega‑3 increased irisin and lowered hs‑CRP and LDL in men with CAD over 8 weeks—favorable heart‑relevant lipid/inflammatory changes.

PubMed ID: 28778393

Raised omega‑3 index and pro‑resolving mediator precursors in PAD patients—biochemical changes relevant to vascular/heart health.

PubMed ID: 30297663

DHA‑rich tuna oil substantially reduced triglycerides (clinically meaningful) in premenopausal women—beneficial to cardiovascular risk profile.

PubMed ID: 29752179

Long‑term EPA+DHA in CAD patients preserved function and increased exercise time—supports cardiac rehabilitation/functional benefits.

PubMed ID: 30227610

1 g EPA + 1 g DHA/day in dialysis patients lowered heart rate, reduced triglycerides and showed signals of improved vagal HRV—direct cardiovascular benefits.

PubMed ID: 29846653

Head‑to‑head DHA vs EPA trial showed DHA modestly increased LDL‑C but shifted LDL toward larger particles and increased LDL turnover — clinically relevant lipid changes.

PubMed ID: 30407633

Randomized crossover feeding study in metabolic‑syndrome subjects showed ~24% triglyceride lowering with dietary DHA — a strong cardiometabolic effect.

PubMed ID: 30735073

DHA lowered resting systolic and diastolic BP vs EPA in healthy adults (cardiovascular benefit).

PubMed ID: 31055222

Omega‑3 index ≥4% strongly associated with prevention of coronary plaque progression in statin‑treated patients (clinically relevant cardiac outcome).

PubMed ID: 31595295

Oily‑fish intake in children modestly lowered triglycerides and raised HDL, favorable for cardiovascular risk profile.

PubMed ID: 31271554

High‑dose omega‑3 in hypertriglyceridemic obese children produced large triglyceride reductions (~39%).

PubMed ID: 32963294

DHA‑enriched foods raised tissue omega‑3 and reduced ambulatory diastolic BP and heart rate—clinically relevant heart/vascular benefits.

PubMed ID: 32044905

Reduced systemic inflammation (TNF‑α, CRP) in hypertensive adults; anti‑inflammatory effects are cardioprotective.

PubMed ID: 34371972

DHA‑rich supplementation in overweight postmenopausal women lowered triglycerides and modestly reduced diastolic BP — supportive of heart health.

PubMed ID: 33933722

High‑dose EPA+DHA in abdominal obesity produced large reductions in VLDL and triglycerides (strong lipid effects relevant to cardiovascular risk).

PubMed ID: 34989797

Large krill‑oil RCT lowered triglycerides substantially and raised EPA/DHA (cardiometabolic marker beneficial for heart health).

PubMed ID: 34982486

In elderly post‑MI patients, larger on‑treatment EPA increases associated with fewer MACE (strong link to cardiovascular protection), though AF risk rose.

PubMed ID: 36050695

Adding 4 g/day EPA+DHA to statin therapy produced large, clinically meaningful reductions in triglycerides, non‑HDL and small dense LDL—strong cardiometabolic benefit.

PubMed ID: 37681568

CCTA trial: EPA+DHA associated with coronary fatty plaque regression, triglyceride lowering and far fewer cardiac events.

PubMed ID: 35953431

Pregnancy dose‑study: 800 mg/day DHA lowered heart rate and increased vagal HRV, indicating improved autonomic cardiac control.

PubMed ID: 38001474

EPA/DHA added to glimepiride improved HbA1c, TG and HDL in T2D over 12 weeks — supports cardiometabolic risk profile improvement.

PubMed ID: 38256336

In dialysis patients high‑dose EPA+DHA lowered remnant cholesterol and improved ankle‑brachial index, indicating improved atherogenic lipids and peripheral arterial status.

PubMed ID: 39163858

4 g/day fish oil markedly lowered triglycerides (~1.5 mmol/L), a major cardiovascular risk factor.

PubMed ID: 38830807

12‑week omega‑3 ethyl esters produced consistent, significant triglyceride and atherogenic lipid reductions in severe hypertriglyceridemia — strong cardiometabolic evidence.

PubMed ID: 39168625

Scallop oil lowered triglycerides (in higher‑TG subgroup) and oxidized‑LDL — modest supportive evidence for blood‑fat mediated heart support.

PubMed ID: 38732508

Dietary intervention including fish oil improved triglycerides and LDL, favorable for cardiovascular risk reduction.

PubMed ID: 41201837

Large RCT in hemodialysis patients: fish‑oil (EPA+DHA) substantially reduced major cardiovascular events and cardiac death (robust clinical benefit).

PubMed ID: 40032221

Large VITAL reanalysis: daily EPA+DHA modestly lowered coronary event/MI risk (consistent cardioprotective signal).

PubMed ID: 10982541

DHA (not EPA) improved forearm vascular reactivity and reduced vasoconstrictor responsiveness—direct vascular/heart‑support physiology.

PubMed ID: 22120130

Large RCT: long-term EPA+DHA markedly reduced AF recurrence after cardioversion (major clinical cardiac endpoint).

PubMed ID: 1971991

Controlled diet study: marine EPA+DHA reduced systolic BP (~−5.1 mmHg) and markedly lowered triglycerides—cardiovascular risk marker improvements.

PubMed ID: 9310278

Large randomized trial showed fish oil substantially reduced total cardiac events and cardiac death—strong direct clinical heart benefit.

PubMed ID: 12010583

In hypertriglyceridemic men, fish oil substantially lowered fasting and postprandial triglycerides (but raised LDL and LDL oxidation), showing strong effects on lipid risk factors.

PubMed ID: 15939062

Fish oil substantially lowered triglycerides (-23%) and decreased small dense LDL in men with an atherogenic profile—strong cardiovascular risk improvement.

PubMed ID: 16960164

Lowering n‑6:n‑3 by adding EPA/DHA reduced fasting and postprandial triglycerides—beneficial for heart risk profile.

PubMed ID: 17158408

Dietary EPA/DHA reduced triglycerides and decreased proportion of small dense LDLs in older adults—favorable for heart health.

PubMed ID: 16983146

Higher plasma DHA linked to slower coronary atherosclerosis progression over ~3 years—prospective human evidence of cardio benefit.

PubMed ID: 19261730

DHA intervention reduced triglycerides and increased HDL (favorable lipid changes for heart health).

PubMed ID: 19933935

Large prospective study: higher serum DHA linked with substantially lower atrial fibrillation risk (epidemiologic cardiac benefit).

PubMed ID: 22110169

Post‑hoc subgroup (post‑MI with diabetes): combined EPA+DHA+ALA associated with markedly fewer ventricular arrhythmia‑related events.

PubMed ID: 22810989

DHA/EPA‑fortified margarine substantially raised erythrocyte EPA/DHA and the omega‑3 index—favourable heart risk biomarker change.

PubMed ID: 22301766

Large RCT subgroup: in statin non‑users, EPA+DHA+ALA associated with a large (borderline significant) reduction in major CV events.

PubMed ID: 25080537

Healthy Nordic diet raised EPA/DHA and produced larger cardiometabolic benefits among compliant participants—relevant to heart health.

PubMed ID: 27279274

180‑day fish‑oil in T2D improved HbA1c and lipid profile—cardiometabolic improvements supportive of heart health.

PubMed ID: 30511840

Fish oil (2 g/day EPA+DHA) reduced systolic BP (~4.5 mmHg) and plasma angiotensin II in hypertensive adults.

PubMed ID: 30900815

EPA+DHA significantly lowered triglycerides (12–16%) and reduced inflammatory signaling—both cardiometabolic risk factors.

PubMed ID: 33840228

Large ACS biomarker case‑cohort: higher long‑chain ω‑3s (including DHA) linked to ≈18% lower cardiovascular death and 27% lower sudden cardiac death odds.

PubMed ID: 35144649

Fish oil in T2DM raised omega‑3 index and substantially lowered triglycerides — clinically relevant CVD risk modification.

PubMed ID: 8729141

Cross‑population data linked higher DHA with lower systolic BP and lower total cholesterol (observational association with heart health).

PubMed ID: 12145002

EPA and DHA (3 g/day) substantially increased arterial elasticity and lowered triglycerides in dyslipidemic adults.

PubMed ID: 15159226

12-week human RCT (4 g/day) lowered plasma TAG, increased platelet EPA/DHA and improved other lipid markers — strong heart-relevant biochemical evidence.

PubMed ID: 18590592

DHA‑enriched pork increased erythrocyte DHA and produced reductions in serum TAG and platelet activation markers.

PubMed ID: 21701167

Prescription omega‑3 reduced platelet activation markers in CAD patients (short‑term RCT), supporting cardiovascular benefit mechanisms.

PubMed ID: 23040588

Higher serum n‑3:n‑6 ratios (including DHA) were associated with less coronary plaque progression in statin‑treated patients (observational).

PubMed ID: 23998969

Large RCT in statin‑treated high‑risk patients: OM3‑FFA (contains DHA) significantly lowered triglycerides and non‑HDL‑C—cardio‑relevant lipid benefits.

PubMed ID: 24528690

Multinational RCT in severe hypertriglyceridemia: dose‑dependent and substantial TG lowering with OM3‑FFA (EPA+DHA) supports heart‑risk reduction.

PubMed ID: 25185754

6:1 EPA:DHA formulation normalized blood omega‑3 and markedly lowered TGs in hypertriglyceridemic subgroup—cardiometabolic benefit.

PubMed ID: 27919362

OM3‑CA reduced apoCIII and favorably shifted LDL subspecies—strong cardiometabolic signal.

PubMed ID: 28410617

High‑dose EPA/DHA markedly raised blood n‑3 levels in atherosclerotic/diabetic patients (clear biochemical effect), despite minimal changes in some clinical clotting markers.

PubMed ID: 29471285

Marked TG reduction and improved inflammatory profile in HIV patients—relevant to heart risk reduction.

PubMed ID: 33041091

Post‑AMI RCT showed increases in DHA/EPA oxylipins, reductions in triglycerides/ApoB/Lp(a) and increased nitric oxide—strong CV biomarker improvements.

PubMed ID: 17825687

Large RCT: prescription omega‑3 added to simvastatin significantly improved non‑HDL cholesterol and triglycerides (cardiovascular risk markers).

PubMed ID: 28664342

RCT in ischemic cardiomyopathy/ICD patients: EPA+DHA reduced ventricular tachyarrhythmia episodes versus placebo.

PubMed ID: 1466329

Fish oil substantially lowered triglycerides in heart transplant patients (randomized open study) — clinically meaningful TG lowering.

PubMed ID: 29223557

Well‑powered RCT: adding 4 g/day ω‑3 to rosuvastatin produced large triglyceride and non‑HDL‑C reductions — cardiometabolic benefit.

PubMed ID: 32805184

Randomized study found EPA or EPA+DHA increased fibrous cap thickness in thin‑cap coronary plaques, suggesting plaque stabilization/vascular benefit.

PubMed ID: 32127335

RCT with DHA-rich fish oil lowered triglycerides, heart rate, raised HDL and reduced artery stiffness (cardiovascular risk markers).

PubMed ID: 2141757

Dose‑dependent incorporation of EPA/DHA with clear, reproducible triglyceride reductions — strong cardiometabolic support.

PubMed ID: 2137901

Large RCT in hypertensive adults: modest, clinically meaningful reductions in systolic/diastolic BP with EPA+DHA.

PubMed ID: 1831755

Dose‑responsive triglyceride lowering in coronary disease patients supports cardiac risk improvement.

PubMed ID: 1534256

Large trial: TG lowered 21% and HDL modestly raised—favorable lipid profile for heart health.

PubMed ID: 1537131

Large RCT showed marked reduction in angiographic restenosis after PTCA (strong cardiovascular benefit).

PubMed ID: 1617510

Coronary patients had clear triglyceride lowering and favorable effect on systolic BP (cardiac patients).

PubMed ID: 7939369

6‑month EPA/DHA after bypass surgery produced a large (~33%) triglyceride reduction and modest insulin effects — favorable for cardiac risk profile.

PubMed ID: 7918310

Large reductions in monocyte tissue factor activity reduce a procoagulant stimulus — potentially cardioprotective.

PubMed ID: 7486485

16‑week RCT in hypertensive adults: 4 g/day EPA+DHA lowered systolic BP modestly and TGs—relevant to cardiovascular support.

PubMed ID: 7891046

High EPA/DHA concentrate markedly lowered triglycerides and reduced blood pressure in combined hyperlipidemia.

PubMed ID: 9665096

DHA-specific lowering of heart rate and improved LV diastolic filling (favorable cardiac physiology).

PubMed ID: 9733153

Moderate-dose EPA+DHA lowered systolic and diastolic BP in mild hypertensives—supports cardiovascular benefit.

PubMed ID: 10454450

Purified DHA significantly reduced 24-hour ambulatory blood pressure and heart rate—direct cardioprotective effects.

PubMed ID: 10189324

Large trial showed modest slowing of coronary atherosclerotic progression—direct heart disease relevance.

PubMed ID: 10479194

Dose-dependent increases in membrane DHA improved heart rate variability in men—cardiac autonomic support.

PubMed ID: 10799369

DHA/EPA lowered TG (~18–20%) and altered LDL/HDL fractions in mildly hyperlipidemic men — beneficial cardiac lipid effects.

PubMed ID: 10919932

Postmenopausal women on fish oil had large TG drops and improved TG:HDL ratio — favorable for heart risk.

PubMed ID: 10938022

In atherogenic men, EPA+DHA greatly reduced fasting and postprandial triglycerides and reduced small dense LDL — cardiometabolic improvements linked to heart benefit.

PubMed ID: 27604770

Prenatal DHA improved sustained attention at age 5—evidence of positive cognitive development from prenatal DHA.

PubMed ID: 40489675

Enteral DHA in septic neonates preserved growth and fat-free mass—important for infant development in critical illness.

PubMed ID: 40791013

Higher prenatal DHA (800 mg/day) improved infant visual attention/learning at 4–6 months — direct infant brain/vision outcome.

PubMed ID: 38552960

Higher‑dose prenatal DHA raised maternal RBC‑DHA and reduced preterm birth risk overall, which supports better infant developmental outcomes indirectly.

PubMed ID: 38680033

Newborn RCT showed reductions in neuronal injury marker and abnormal MRI with DHA in infants with hyperbilirubinemia—neuroprotective evidence.

PubMed ID: 37268036

Faster early growth partially explained better cognitive and language scores in very preterm infants in omega‑3 trial context.

PubMed ID: 37294565

High‑dose neonatal DHA increased average IQ in extremely preterm infants — strong infant brain development signal.

PubMed ID: 36680919

Large pregnancy trial: high‑dose maternal DHA and achieving higher blood DHA strongly lowered very early and overall preterm birth rates (important for infant neurodevelopment).

PubMed ID: 36014916

Algal DHA supplementation in lactating women significantly raised breast‑milk DHA and improved n‑6/n‑3 balance—directly supports infant DHA exposure for brain/retina development.

PubMed ID: 36657936

Pooled RCT analysis: women with low baseline DHA who received high‑dose DHA had substantially lower early/preterm birth—important for infant neurodevelopmental outcomes.

PubMed ID: 35652296

High‑dose maternal DHA showed no overall 18–22 month neurodevelopment benefit but a subgroup (<27 wk GA) had better language scores—selective infant developmental benefit.

PubMed ID: 34210228

EPA/DHA supplements in pregnant women raised maternal and cord DHA (direct biomarker evidence relevant to fetal brain/vision development).

PubMed ID: 34494106

Prenatal DHA produced substantial, genotype‑dependent changes in infant plasma metabolome at 3 months — mechanistic support for developmental effects.

PubMed ID: 34543890

Prenatal DHA (400 mg/day) improved 5‑year cognitive outcomes (memory, quantitative) in offspring of mothers with specific FADS2 genotype — strong developmental benefit in subgroup.

PubMed ID: 34552200

800 mg/day prenatal DHA significantly increased maternal and cord DHA and maternal–infant DHA equilibrium — strong biomarker support for fetal DHA supply.

PubMed ID: 31963702

Toddler formula with microencapsulated tuna oil substantially increased whole‑blood DHA and omega‑3 index — relevant to infant/toddler brain/retina DHA status.

PubMed ID: 32823606

Prenatal supplementation (200 mg DHA/day) raised maternal RBC DHA/omega‑3 index—improves substrate availability for fetal brain/vision development.

PubMed ID: 31030946

ELBW infants receiving fish‑oil containing lipid emulsion showed earlier and higher electrophysiological brain maturation — strong neonatal DHA‑relevant evidence.

PubMed ID: 30614004

DHA reduced severe ROP in very low‑birth‑weight infants, a direct infant vision benefit.

PubMed ID: 29316994

Maternal DHA supplementation showed no group‑level neurodevelopment benefit at 5–6 y, but maternal DHA status correlated with some child cognitive measures (associational support).

PubMed ID: 30392575

Dose–response analysis linked higher maternal DHA intake to substantially fewer very early preterm and very low birthweight infants — strong perinatal outcome with implications for infant neurodevelopment/vision.

PubMed ID: 29098783

Large trial: although overall cognition outcomes were null, higher breastmilk DHA associated with small improvements in infant attention/verbal outcomes and some subgroup benefits.

PubMed ID: 28752418

Maternal fish‑oil from mid‑pregnancy to postpartum modestly improved infant communication scores at 4 months (developmental benefit).

PubMed ID: 18519483

Very preterm infants had improved problem solving and ERP memory markers after DHA+ARA supplementation.

PubMed ID: 26846324

Daily enteral DHA in preterm infants significantly raised blood DHA and supported linear growth (direct neonatal DHA delivery and growth benefit).

PubMed ID: 27499448

Economic analysis of an RCT subset found prenatal DHA associated with lower infant hospital costs (fewer early preterm births), indicating improved early infant health outcomes.

PubMed ID: 27362506

Prenatal DHA (600 mg/day) produced more stable sustained attention and faster habituation in infants 4–9 months—direct evidence for early brain/attention development effects.

PubMed ID: 24427279

Maternal 400 mg/day DHA raised maternal RBC DHA and reduced risk of suboptimal early infant language and 2-month visual acuity (large RCT).

PubMed ID: 25039804

Maternal/infant supplementation increased infant RBC DHA substantially and altered inflammatory cytokines in infants — directly relevant to infant development milieu.

PubMed ID: 24925713

600 mg/day maternal DHA markedly raised maternal and neonatal membrane DHA and plasma DHA — direct biomarker evidence relevant to infant brain/vision substrate.

PubMed ID: 24045792

Dietary counseling modestly increased maternal DHA and total n‑3 by third trimester — relevant to fetal DHA exposure.

PubMed ID: 23963690

Parenteral fish‑oil emulsions in VLBW infants raised DHA and produced major reductions in severe ROP and cholestasis—direct and large benefits for infant vision and overall neonatal outcomes.

PubMed ID: 23433688

Maternal DHA supplementation (600 mg/day) increased fetal HRV and improved newborn motor and autonomic behavior on NBAS—strong evidence for neurobehavioral maturation.

PubMed ID: 23531328

Maternal DHA lengthened gestation and increased newborn size—a perinatal outcome that supports infant health and development though not direct cognitive/visual measures.

PubMed ID: 23426033

Large RCT in pregnancy: 600 mg/day DHA increased maternal/cord DHA, modestly prolonged gestation and produced heavier/longer infants with fewer very early preterm births—supports neonatal development.

PubMed ID: 22237883

Preterm infants receiving fish-oil containing lipid emulsion had increased plasma/RBC DHA and EPA without short-term safety issues—improves neonatal DHA status.

PubMed ID: 22348468

High‑dose infant fish oil raised DHA and produced small improvements in specific early communicative gestures (developmental domain).

PubMed ID: 21593355

Maternal dietary counseling improved cord DHA sufficiency indices and lowered ETA, supporting better DHA supply to infants — relevant to brain/vision development.

PubMed ID: 21849598

Maternal dietary salmon (EPA/DHA) reliably increased maternal and cord blood EPA/DHA—supports biological delivery needed for fetal brain/vision development.

PubMed ID: 19358928

Maternal plasma PL and RBC DHA strongly correlate with cord RBC DHA, validating biomarkers used to assess DHA exposure important for infant brain/vision development.

PubMed ID: 19141765

High‑DHA feeds in very preterm infants produced a modest MDI improvement in girls at 18 months—subgroup developmental benefit.

PubMed ID: 18326591

Maternal 400 mg/day DHA increased odds of better infant visual acuity at 60 days (adjusted OR ≈3.37), direct developmental outcome.

PubMed ID: 18446020

Randomized trial: 200 mg/day maternal DHA from mid‑pregnancy through lactation clearly increased maternal, milk and infant DHA status—direct support for infant brain/vision substrate.

PubMed ID: 17393217

Maternal DHA improved infant visual acuity at 4 months (small RCT)—direct developmental vision effect.

PubMed ID: 17957152

Maternal fish oil increased breast‑milk DHA/EPA and was associated with better infant DHA status and some developmental scores.

PubMed ID: 17490978

Pregnancy fish‑oil supplementation significantly increased maternal and cord‑blood DHA, directly supporting fetal DHA supply for brain/vision.

PubMed ID: 17023713

Placental transporter expression correlated with maternal/cord DHA, implicating mechanisms of fetal DHA transfer relevant to brain/vision.

PubMed ID: 15333721

Randomized trial in term breast‑fed infants: DHA‑enriched food raised RBC DHA and produced a meaningful improvement in visual acuity by 12 months.

PubMed ID: 12882824

Although supplementation did not change ERG outcomes overall, infants with higher cord DHA had more sensitive retinas—status-dependent association relevant to infant vision/brain.

PubMed ID: 12636950

Third-trimester DHA increased gestation length (longer gestation can benefit infant development; indirect support).

PubMed ID: 11916764

Maternal DHA in lactation raised milk DHA, increasing infant DHA intake relevant to brain/vision development.

PubMed ID: 12036817

Feeding n‑3‑enriched egg yolks to infants markedly raised erythrocyte DHA — biomarker consistent with enhanced brain/vision development potential.

PubMed ID: 11864865

Randomized RCT: LCP (including DHA) improved infant visual acuity and stereoacuity — strong evidence for infant vision/brain development.

PubMed ID: 11161546

Feeding formula with LCP phospholipids raised infant plasma DHA close to breast‑fed levels — supportive biomarker evidence for development.

PubMed ID: 8949693

Preterm infants receiving DHA-containing feeds showed faster VEP maturation and higher RBC DHA (robust infant CNS signal).

PubMed ID: 8541278

Maternal third‑trimester fish oil (2.7 g/d) clearly increased infant/umbilical DHA at birth—direct biochemical support for infant brain/vision substrate.

PubMed ID: 11694666

Maternal cod-liver oil increased umbilical/cord DHA levels and higher neonatal DHA associated with modestly longer gestation; biomarker support for fetal DHA exposure.

PubMed ID: 33339438

Randomized trial: MMS containing DHA raised breastmilk and maternal blood DHA — direct evidence supporting infant DHA supply for brain/retina development.

PubMed ID: 39702768

AA+DHA reduced severe ROP and early thrombocytopenia in extremely preterm infants—clinically meaningful vision/hematologic neonatal outcomes.

PubMed ID: 37513559

Higher PUFA/DHA intake during complementary feeding associated with better cognitive and motor development at 12 months in VLBW infants (prospective evidence).

PubMed ID: 37120902

Longitudinal profiling showed enteral AA:DHA supplementation raises circulating AA/DHA proportions in extremely preterm infants—supports biochemical delivery to infant tissues.

PubMed ID: 38061271

Duplicate entry (same strong white‑matter RCT) emphasizing direct infant brain development evidence.

PubMed ID: 35495419

AA+DHA halved severe ROP risk in extremely preterm infants—strong evidence for protection of infant vision development.

PubMed ID: 34728723

Maternal algae‑DHA sharply increased breast‑milk DHA and DHA:AA ratio—biomarker change that supports infant brain and retinal accretion.

PubMed ID: 33358843

Dose‑response infant RCT showed rapid, dose‑dependent rises in whole‑blood DHA and ARA—directly applicable to infant nutrient repletion for brain/retina.

PubMed ID: 33523106

Enteral AA+DHA reduced severe ROP (vision) in extremely preterm infants—strong clinically meaningful infant visual outcome.

PubMed ID: 33159163

Maternal fish‑oil in lactation substantially raised breastmilk DHA/EPA (increases infant DHA supply critical for brain/vision development).

PubMed ID: 30871048

Formula DHA/AA increased infant LCPUFAs but FADS genotypes modulate response—relevant to personalized infant nutrient status.

PubMed ID: 31371795

Large randomized SQ‑LNS trial raised infant plasma DHA at 12 months (substantial biomarker improvement relevant to brain/vision development).

PubMed ID: 31024091

Observational cohort showed infant plasma DHA closely tracks maternal levels—important for perinatal DHA supply to brain/vision.

PubMed ID: 30649163

SQ‑LNS with DHA/ARA improved early locomotor scores and transient length gains—evidence of developmental benefit in infancy.

PubMed ID: 30311214

Longitudinal randomized infant LCPUFA exposure produced durable functional, connectivity and structural brain differences at age ~9.

PubMed ID: 30392581

Maternal DHA+ARA supplementation increased newborn brain volumes (notably males)—strong developmental structural evidence.

PubMed ID: 27276431

Infant formula with fixed DHA but varying ARA affected lymphocyte ARA and B‑cell activation—relevant to development and immune maturation.

PubMed ID: 29413361

Pregnancy dosing study provided direct quantitative DHA dose targets to reach RBC and mature milk DHA thresholds required to support infant supply.

PubMed ID: 27747986

Infant LCPUFA exposure produced durable electrophysiological differences in attention/inhibition—strong neural development evidence.

PubMed ID: 26970335

Maternal supplementation increased milk DHA and reduced IgE allergy—supports infant DHA exposure and health.

PubMed ID: 27571269

Infant formula DHA/ARA supplementation produced large increases in DHA‑ and ARA‑containing plasma phospholipids (biomarker of development).

PubMed ID: 27391868

Higher‑DHA formulas raised infant RBC DHA to breastfed levels — robust biochemical support for DHA availability in infancy.

PubMed ID: 26205427

Cross-sectional data showing much lower DHA/ARA in preterms vs term infants—supports need for supplementation for development.

PubMed ID: 25997653

Enteral DHA emulsions maintained/increased blood DHA in very preterm infants (prevents deficiency relevant to brain/vision).

PubMed ID: 26424477

Higher AA:DHA (2:1) formula in very preterm infants led to better psychomotor scores at 2 years (strong developmental outcome).

PubMed ID: 24863250

Human milk fortified with DHA/ARA raised infant plasma DHA and ARA after 28 days (biomarker relevant to development).

PubMed ID: 23783296

LCPUFA‑supplemented formula produced faster information‑processing at age 6—relevant to early brain development.

PubMed ID: 23710566

Cross‑population study found higher RBC‑DHA in breastfed infants correlated with better early motor optimality—supports developmental benefit.

PubMed ID: 23803884

Infant LCPUFA given in early life produced later improvements on specific cognitive and language tasks between ages 3–6.

PubMed ID: 23340492

Randomized maternal n‑3 LCPUFA intervention lowered maternal/cord n‑6:n‑3 and raised cord DHA, associated with larger birth size — strong support for fetal DHA transfer.

PubMed ID: 22945403

Daily DHA/EPA supplementation from birth improved infant erythrocyte DHA by 6 months (clear biochemical provision), though clinical allergy outcomes were unchanged.

PubMed ID: 21295417

Infant RCT: DHA in formula produced a measurable improvement in mental development at 18 months (direct developmental endpoint).

PubMed ID: 20624152

VLBW RCT: early DHA+ARA improved sustained attention at 20 months; plasma DHA correlated with attention—direct infant neurodevelopment benefit.

PubMed ID: 20130095

Large RCT demonstrating DHA supplementation in formula improved infant visual acuity at 12 months (strong developmental evidence).

PubMed ID: 19765006

Randomized trials pooled showed better means‑end problem solving in infants fed DHA+ARA.

PubMed ID: 20335550

Dose‑dependent increases of DHA/EPA in serum and breast adipose tissue indicate effective maternal/tissue delivery—directly relevant to supporting infant brain/vision nutrients.

PubMed ID: 29092879

Large infant RCT: one egg/day increased plasma DHA and choline—direct nutritional support for brain/vision substrates.

PubMed ID: 35575618

Choline plus DHA supplementation increased maternal plasma/RBC DHA — improves maternal→fetal/infant DHA availability.

PubMed ID: 37806075

Large pregnancy trial: higher maternal DHA increased maternal DHA status and associated with longer gestation and fewer preterm births—important for infant neurodevelopmental outcomes.

PubMed ID: 40412614

Maternal DHA (and nutrient combinations) associated with infant EEG/ERP differences at 1 and 6 months, indicating effects on early brain function.

PubMed ID: 1386065

Provision of long‑chain n‑3s in VLBW infants prevented deficits in retinal function—direct functional evidence relevant to infant brain/vision development.

PubMed ID: 8615350

Marine n‑3 LCPUFA in preterm infants improved early visual acuity in subgroup—functional infant vision/brain outcome.

PubMed ID: 11248877

Multicenter randomized preterm formula trial: high‑ALA formula maintained RBC DHA comparable to human milk—strong evidence of DHA status maintenance.

PubMed ID: 8979282

Large randomized infant feeding trial: RBC DHA increased markedly with supplemented formulas though no vision/growth differences over first year.

PubMed ID: 10443966

Tissue DHA biomarkers reflected formula intake and correlated with visual neurodevelopmental measures (VEP/ERG).

PubMed ID: 11528489

Quantitative human data in preterm infants show ~62% DHA net retention after supplementation—strong bioavailability evidence for infant brain/vision.

PubMed ID: 11972740

Lower early DHA status in infants associated with lower developmental scores at 1 year (direct infant neurodevelopment evidence).

PubMed ID: 14569405

Formula with long‑chain PUFA raised infant plasma DHA to breast‑milk levels—strong biomarker evidence supporting DHA supply for infant brain/vision development.

PubMed ID: 12509593

Maternal cod‑liver oil (DHA) resulted in ~4‑point higher cognitive composite in children at age 4—strong evidence for prenatal DHA benefit.

PubMed ID: 16540798

Higher preformed DHA in term infant formula markedly raised infant RBC DHA—supports effective DHA provisioning during infancy.

PubMed ID: 21178076

Prenatal 400 mg/day DHA significantly raised breast‑milk DHA—directly increases infant DHA exposure relevant to brain/vision development.

PubMed ID: 22008957

Randomized infant formula trial: higher formula DHA produced dose‑dependent increases in infant plasma/erythrocyte DHA; 0.33% matched human milk composition.

PubMed ID: 26169870

Regular salmon in complementary feeding significantly increased infant RBC/plasma EPA and DHA—direct provision of preformed LC‑DHA to infants.

PubMed ID: 26378118

ω‑3‑enriched IV lipid in preterm neonates raised EPA/DHA and lowered IL‑6/IL‑8—supports neurodevelopmental environment and DHA supply.

PubMed ID: 26247968

Chia (ALA) in pregnancy/nursing raised maternal RBC EPA and transiently increased breast‑milk DHA in early nursing—relevant to infant DHA supply.

PubMed ID: 25633498

High‑oleic RUTF preserved/increased plasma DHA/EPA in malnourished children—important for developmental DHA availability.

PubMed ID: 29843467

Fortified human milk with preformed DHA + ALA increased infant plasma/RBC DHA/EPA within 21 days—direct delivery of DHA to preterm infants.

PubMed ID: 32725293

Two fish meals/week in women of childbearing age increased EPA/DHA, improving maternal n‑3 status relevant to fetal/infant DHA supply.

PubMed ID: 36418565

Algal DHA 250 mg/day reliably doubled serum DHA in vegans — practical evidence that supplementation elevates maternal/infant DHA potential.

PubMed ID: 35853297

Early‑pregnancy plasma DHA associated with larger longitudinal fetal growth trajectories — supports role in fetal development.

PubMed ID: 37892412

Large analysis: maternal fish intake and breastfeeding both associated with higher infant serum DHA at ~5 months — direct relevance to infant DHA status.

PubMed ID: 41270711

Pregnant Indian women had markedly lower erythrocyte EPA/DHA vs Australian women — indicates need for DHA in pregnancy for infant LCPUFA status.

PubMed ID: 7478826

LC‑PUFA supplemented formula infants scored higher on early neurodevelopmental tests and had higher circulating DHA/AA.

PubMed ID: 8726246

DHA+AA supplemented formula increased early visual acuity and blood DHA/AA in term infants (transient but functional benefit).

PubMed ID: 8958000

Same as above (biochemical increases in LCPUFA in preterms); included for emphasis on infant substrate delivery.

PubMed ID: 9196357

Erythrocyte LC‑PUFA composition correlated strongly with developmental quotient, supporting an association between DHA status and development.

PubMed ID: 9702915

Dietary DHA produced VEP acuity improvements and RBC profiles similar to breast-fed infants (direct vision/development evidence).

PubMed ID: 9552137

DHA-supplemented formulas normalized RBC DHA to breast-fed levels; visual acuity advantages were small/inconclusive but biomarker effect supports development.

PubMed ID: 10102659

Supplementing term infant formula with DHA+AA normalized infant plasma and RBC DHA/AA to breast-fed levels (biomarker normalisation relevant to development).

PubMed ID: 10755457

Randomized trial showed ~+7 points on Bayley MDI at 18 months with early DHA+AA supplementation—meaningful neurodevelopmental effect.

PubMed ID: 11144440

DHA‑enriched formula produced breastfed‑like DHA status and clear improvements in electrophysiologic measures and visual acuity up to 1 year.

PubMed ID: 10941962

Preterm formula with DHA (and AA) raised tissue DHA and was safe long‑term—supports physiological basis for development.

PubMed ID: 10653329

High‑DHA term infant formula maintained DHA vs standard formula; biochemical preservation relevant to brain/vision development despite AA lowering.

PubMed ID: 11483801

Large multicenter RCT in preterms showed improved VEP acuity and some motor development benefits with AA+DHA.

PubMed ID: 12032520

Premature infants fed DHA+ARA gained weight faster and showed no safety concerns; growth and biochemical data support developmental benefit potential.

PubMed ID: 12838196

Term infants receiving DHA+ARA formula had improved VEP acuity and higher RBC‑DHA at 1 year—functional vision/developmental benefit.

PubMed ID: 15069395

Preterm LCPUFA supplementation improved Bayley MDI (notably in boys) and growth—strong developmental evidence.

PubMed ID: 14985680

Pregnancy fish-oil RCT raised maternal and neonatal EPA/DHA — strong prenatal biochemical provisioning relevant to infant brain/vision development.

PubMed ID: 15298564

Maternal fish-oil increased breast-milk DHA/EPA (biological substrate for infant brain/vision), though clinical infant outcomes not shown here.

PubMed ID: 15812447

Preterm infants fed DHA+ARA had improved growth and Bayley developmental scores—robust RCT evidence supporting infant development.

PubMed ID: 15718356

Preterm infants fed DHA+ARA showed favorable body-composition changes and no adverse growth/bone effects, supporting healthy physical development along with potential neurodevelopmental benefits.

PubMed ID: 15817866

Term-infant RCT showed better VEP acuity during the first year and marked RBC DHA increases—strong infant brain/vision evidence.

PubMed ID: 16483397

In PKU infants DHA supplementation prevented large declines in erythrocyte DHA and may have helped visual maturation—strong infant developmental support.

PubMed ID: 17185423

Maternal high‑dose fish oil modestly improved children's eye–hand coordination at 2.5 years with cord‑blood DHA/EPA correlations.

PubMed ID: 16923694

Maternal cod‑liver oil increased maternal and infant DHA delivery—biochemical transfer supportive of infant development.

PubMed ID: 17240089

DHA/ARA infant formulas produced age‑4 visual acuity comparable to breast‑fed children (developmental outcome).

PubMed ID: 17912568

Large trial: DHA+ARA in soy formula significantly raised infant RBC and plasma DHA/ARA—biochemical support for development.

PubMed ID: 19118992

Maternal DHA+AA supplementation increased breast‑milk DHA and AA—direct transfer to nursing infants that supports development.

PubMed ID: 18842793

Preterm infants with higher DHA had better visual acuity at 4 months—functional developmental effect.

PubMed ID: 17237316

Multinutrient + DHA regimen after MI lowered hs‑CRP — evidence of systemic inflammation reduction.

PubMed ID: 17391558

DHA reduced stimulated neutrophil superoxide production and correlated with erythrocyte DHA — direct anti‑inflammatory cellular effect.

PubMed ID: 17875549

3 g/day fish oil for 24 weeks lowered lupus disease activity and oxidative stress and improved endothelial markers.

PubMed ID: 17199721

Long‑chain n‑3 reduced CRP and IL‑6 and triglycerides in a 12‑week randomized crossover trial.

PubMed ID: 18241260

High‑dose DHA reduced eczema severity and IgE production—anti‑inflammatory effect in atopic disease.

PubMed ID: 18930251

Children receiving fish oil had smaller rises in TGF‑β1 and fewer illnesses, indicating anti‑inflammatory/immunoregulatory effects.

PubMed ID: 18685141

PUFA added to standard therapy produced a large reduction in proteinuria and hematuria in IgA nephropathy, consistent with potent anti‑inflammatory/renal immune effects.

PubMed ID: 18982439

n‑3 PUFA lowered cytokines and the n6:n3 ratio in dilated cardiomyopathy patients, consistent anti‑inflammatory effects.

PubMed ID: 19515734

Widespread downregulation of inflammatory pathways (NF‑κB, eicosanoid synthesis) in PBMCs after 26 weeks EPA+DHA (strong molecular anti‑inflammatory signal).

PubMed ID: 19685375

Shift in leukotriene production toward anti‑inflammatory LTB5 and increased LTB5/LTB4 ratio in patients on n‑3 PUFA.

PubMed ID: 19158225

3 g/day DHA for 3 months produced significant reductions in CRP, IL‑6 and neutrophils in men with high triglycerides (robust anti‑inflammatory biomarker changes).

PubMed ID: 19461006

6 months of EPA+DHA lowered CRP in end‑stage renal disease patients (clinically relevant reduction in systemic inflammation).

PubMed ID: 19595382

Long‑term n‑3 intervention in elderly men reduced IL‑18 by about 10% (modest anti‑inflammatory effect in a large trial).

PubMed ID: 20542512

Higher plaque EPA associated with lower plaque inflammation and instability (tissue‑level anti‑inflammatory effect).

PubMed ID: 20071644

Attenuated meal-induced FMD decline and enhanced microvascular RH suggest protection against meal-related vascular inflammation.

PubMed ID: 20795425

Large symptomatic pain reductions and less analgesic use implicate substantial anti-inflammatory effect.

PubMed ID: 20545703

EPA‑enriched formula reduced airway inflammation markers (FeNO) in asthmatic children (small RCT inflammatory endpoint).

PubMed ID: 20572767

Adjunct ω‑3 + low‑dose aspirin reduced periodontal inflammatory biomarkers (salivary RANKL, MMP‑8) and improved clinical inflammation outcomes (aspirin confound).

PubMed ID: 22136963

Infant lipid emulsion RCT substantially lowered TNF‑α — strong anti-inflammatory evidence.

PubMed ID: 21708809

High maternal DHA reduced BPD and hay fever in subgroups — clinically important anti-inflammatory/allergy outcomes.

PubMed ID: 22079797

Oral DHA in neonatal sepsis lowered IL‑1β and increased leukocyte DHA — evidence of inflammation control.

PubMed ID: 21045648

Dry‑eye RCT: symptomatic and tear volume improvements consistent with reduced ocular surface inflammation (small clinical trial).

PubMed ID: 22114792

EPA+DHA supplementation during chemotherapy reduced CRP and IL-6 and stabilized oxidative stress markers—clear systemic anti-inflammatory effect in this setting.

PubMed ID: 23023905

8‑week reduction in TNF‑α and IL‑2 indicates anti‑inflammatory activity in T2D patients.

PubMed ID: 22929118

Marked gene‑expression changes affecting immune and lipid pathways suggest inflammation modulation.

PubMed ID: 23238663

Lowered platelet 8‑isoprostane and stimulated ROS production in hypertensive/diabetic patients—reduced oxidative/inflammatory platelet activation.

PubMed ID: 24568073

Children with ADHD: EPA+DHA lowered CRP and IL‑6 and increased antioxidant enzymes—clear anti-inflammatory marker changes.

PubMed ID: 24190860

High‑dose EPA+DHA reduced fever response to LPS and produced dose-dependent RBC incorporation—modest attenuation of acute inflammatory response.

PubMed ID: 23328126

12 weeks of 4 g/day fish oil reduced adipose macrophages and MCP‑1 and increased capillaries—clear tissue anti‑inflammatory remodeling.

PubMed ID: 23861993

In RR‑MS patients, 12 months of 4 g/day fish oil produced large (~40–50%) reductions in multiple inflammatory cytokines—strong anti‑inflammatory biomarker evidence.

PubMed ID: 24970858

DHA + low‑dose aspirin adjunct produced significant reductions in local gingival inflammation markers (hsCRP, IL‑1β) and pocket depth.

PubMed ID: 25039804

Infant supplementation reduced several stimulated inflammatory cytokines at selected time points in infants at genetic risk for type 1 diabetes.

PubMed ID: 24048161

SMOFlipid in very preterm neonates reduced F2‑isoprostanes (lipid peroxidation marker) suggesting antioxidant/anti‑inflammatory effect.

PubMed ID: 25268838

Markedly shifted neutrophil eicosanoid production from LTB4 to LTB5 and increased 5-HEPE—strong anti-inflammatory mechanistic signal.

PubMed ID: 24643636

Omega‑3 supplementation in hemodialysis patients decreased depressive symptoms and was accompanied by modest anti‑inflammatory marker changes (CRP, ferritin, IL‑10/IL‑6).

PubMed ID: 24641624

Large set of differentially expressed immune genes and enrichment of ER stress/apoptosis/cell‑cycle pathways after fish oil.

PubMed ID: 24655407

Perioperative fish‑oil blunted IL‑6/TNF rise and markedly reduced postoperative infections (robust anti‑inflammatory/clinical effect).

PubMed ID: 25307169

DHA‑rich supplement in horses reduced airway neutrophilia and clinical signs (clear anti‑inflammatory effect in airway disease).

PubMed ID: 24746829

Significant reductions in hs‑CRP, TNF‑α, sICAM‑1, sVCAM‑1 and oxLDL indicate strong anti‑inflammatory effects.

PubMed ID: 26074314

EPA and DHA differentially down‑regulated multiple inflammation‑related genes in PBMCs (strong mechanistic anti‑inflammatory evidence).

PubMed ID: 26340264

In pregnant obese women EPA+DHA lowered adipose and placental IL6/IL8/TNFα and systemic CRP (clear anti‑inflammatory tissue and systemic effects).

PubMed ID: 26077874

DHA added to iron therapy decreased hs‑CRP versus iron alone (clinical marker of inflammation improved).

PubMed ID: 26247967

RBC DPA inversely associated with CRP at baseline and increased with supplementation (supports anti‑inflammatory association).

PubMed ID: 25976467

Sickle cell study showed reduced NF‑κB and inflammatory/adhesion markers (direct inflammation control).

PubMed ID: 27281302

DHA significantly reduced IL‑18 and increased anti‑inflammatory adiponectin in at‑risk adults (direct inflammatory marker changes).

PubMed ID: 27806350

Perioperative DHA reduced neonatal opioid requirements post-cardiac surgery, consistent with analgesic/anti-inflammatory effects in the surgical inflammatory context.

PubMed ID: 27394149

Perioperative neonatal DHA reduced proinflammatory cytokines (IL‑1β, IL‑6) and increased IL‑10 timing—clear anti‑inflammatory signal.

PubMed ID: 29031393

Maternal DHA lowered pro‑inflammatory markers and raised anti‑inflammatory signals in mothers and infants (small RCT).

PubMed ID: 29173199

Prenatal supplementation increased SPM precursors in cord blood—biological evidence for enhanced resolution of inflammation at birth.

PubMed ID: 28075381

Decreases in IL‑6, TNF‑α and sPLA2 activity in MCI subjects support systemic anti‑inflammatory effects.

PubMed ID: 28987470

High‑dose omega‑3 in DMD significantly reduced IL‑1β and IL‑6 and increased IL‑10—strong anti‑inflammatory biomarker evidence.

PubMed ID: 28758717

Reduced activated PMNs in wound fluid and improved wound metrics indicate local anti‑inflammatory effects.

PubMed ID: 28651701

Reduced oxidative stress markers and increased antioxidant capacity in early schizophrenia correlated with symptom improvement (inflammation/oxidative stress modulation).

PubMed ID: 28131045

High‑dose EPA/DHA produced consistent changes in inflammation‑related gene transcripts (mechanistic anti‑inflammatory evidence).

PubMed ID: 29195133

Fish oil modulated B‑cell cytokine secretion (IL‑10, TNFα) and decreased IgM production—immune/inflammatory modulation at the cellular level.

PubMed ID: 28112528

Omega‑3 lowered hs‑CRP in men with CAD over 8 weeks, indicating reduced systemic inflammation.

PubMed ID: 28778393

Marked increases in omega‑3 index and pro‑resolving mediator precursors indicate strong anti‑inflammatory potential.

PubMed ID: 29735019

High‑dose EPA+DHA produced large, consistent reductions in IL‑6, IL‑1β and TNF‑α in older adults—strong anti‑inflammatory evidence.

PubMed ID: 29385062

RCT in gestational diabetes documented downregulation of inflammatory genes (IL‑1, TNF‑α) and upregulation of PPAR‑γ — strong anti‑inflammatory signal.

PubMed ID: 29940888

Prenatal EPA‑rich regimen reduced multiple maternal inflammatory cytokines (IL‑6, TNFα, IL‑15) — supports inflammation control (close mechanistic relevance).

PubMed ID: 30097463

DHA formulation in sickle cell decreased adhesion/inflammatory markers (sP‑selectin, sE‑selectin) and pain diary outcomes — clinically relevant anti‑inflammatory/vascular effects.

PubMed ID: 31831363

DHA increased PPAR‑γ activity in PBMCs in T2DM patients, consistent with anti‑inflammatory transcriptional effects.

PubMed ID: 32856190

DHA ± folic acid reduced inflammatory cytokines (IL‑1β, IL‑6) in MCI patients—evidence of systemic inflammation lowering.

PubMed ID: 32867199

High‑dose EPA/DHA adjunct improved periodontal inflammation and bleeding—clinical anti‑inflammatory effect.

PubMed ID: 32436902

Adjunct ω‑3 improved periodontal inflammation markers (probing depth, attachment level, gingival index) — clinical anti‑inflammatory effect.

PubMed ID: 32044905

Clear reductions in TNF‑α and CRP after 3 months of fish oil in hypertensive adults — strong anti‑inflammatory biomarker effect.

PubMed ID: 34728061

CMD patients showed low downstream pro‑resolving mediators despite high precursors, implicating EPA/DHA pathways in inflammation resolution (mechanistic evidence).

PubMed ID: 33812168

EPA reduced vascular inflammatory markers (CCL2, VCAM1) in humans and mice — strong evidence for inflammation control.

PubMed ID: 34684525

Eating salmon lowered IL‑6 modestly in overweight adults — evidence of reduced systemic inflammation.

PubMed ID: 34578993

Marked, oil‑dependent changes in activation‑induced T‑cell transcripts after increasing EPA/DHA in immune cells — mechanistic inflammation modulation.

PubMed ID: 34516692

Small COVID RCT reported favorable changes in inflammatory markers with DHA+EPA (supports inflammation control).

PubMed ID: 36005883

hs‑CRP reductions correlated with symptom improvement in EPA 4 g/day group (direct inflammation biomarker association).

PubMed ID: 36409163

Blue mussel lipid extract reduced TNF‑α and improved insulin resistance and TGs (direct anti‑inflammatory biomarker changes).

PubMed ID: 36414947

Omega‑3 added to periodontal therapy produced significantly greater reductions in pocket depth and attachment loss—clear local anti‑inflammatory/clinical effect.

PubMed ID: 29471285

DHA in HIV patients markedly reduced triglycerides and adipose inflammatory gene expression and hsCRP.

PubMed ID: 37179297

Adjunct high‑dose fish oil improved deep periodontal pocket healing and reduced periopathogens — anti‑inflammatory clinical effect.

PubMed ID: 37532570

Self‑emulsifying EPA rapidly raised EPA and EPA‑derived anti‑inflammatory metabolites (18‑HEPE etc.).

PubMed ID: 39275147

Combination product reduced eczema severity and topical steroid need, consistent with reduced skin inflammation.

PubMed ID: 38518540

One‑year 1 g/day EPA+DHA reduced multiple pro‑inflammatory eicosanoids and increased some resolvins — strong mechanistic inflammation control evidence.

PubMed ID: 38732601

Synbiotic formulation with n‑3 rapidly and substantially raised pro‑resolving LM precursors (18‑HEPE/5‑HEPE) more than fish oil — strong pro‑resolution mechanistic signal.

PubMed ID: 39770887

Fish‑oil intervention reduced several pro‑inflammatory arachidonic acid–derived oxylipins and raised n‑3 index.

PubMed ID: 40644954

n‑3 plus micronutrients modestly reduced an aggregated inflammation score in older adults — supportive of systemic inflammation reduction.

PubMed ID: 40405290

DHA preserved immunologic and cytokine responses during chemotherapy, indicating reduced treatment‑related immune suppression/inflammatory disturbance.

PubMed ID: 41515121

Dietary increases in EPA/DHA (esp. EPA) associated with clinically meaningful reductions in pain interference in migraine, consistent with anti-inflammatory mechanisms.

PubMed ID: 36904299

High‑dose DHA raised antioxidant capacity and lowered MDA and IL‑6 — clear anti‑inflammatory/anti‑oxidative biomarker changes.

PubMed ID: 31006007

Clear, dose‑dependent increases in EPA/DHA‑derived anti‑inflammatory oxylipins and SPM precursors—strong mechanistic anti‑inflammatory evidence.

PubMed ID: 33041091

AMI patients had reduced proinflammatory prostanoid/leukotriene levels and increased DHA/EPA epoxides—clinically relevant anti‑inflammatory biomarker changes.

PubMed ID: 35247847

12‑week EPA+DHA increased tissue EPA/DHA and lowered inflammatory gene expression and SPM precursors in normal‑weight adults (robust tissue‑level anti‑inflammatory signal).

PubMed ID: 37121228

Randomized ARA+DHA lowered IL‑6 and other proinflammatory cytokines in very preterm infants—strong direct anti‑inflammatory evidence.

PubMed ID: 38603973

Large observational proteomic associations linked higher DHA/AA to lower inflammatory proteins (IL‑6, CCL7) though correlational.

PubMed ID: 7874893

ICU study with fish‑oil formula showed clinical benefits (fewer infections/shorter LOS) and higher plasma EPA/DHA, consistent with immune/inflammatory modulation.

PubMed ID: 27578110

DHA‑enriched fish oil in T2DM lowered macrophage activation marker (sCD163) and triglycerides—evidence of anti‑inflammatory effect.

PubMed ID: 39181037

EPA/DHA (with/without HMB) reduced multiple inflammatory cytokines and improved lean mass in COPD patients.

PubMed ID: 40671417

Krill oil during alternate‑day fasting reduced TNF‑α and CRP more than placebo—clear anti‑inflammatory changes.

PubMed ID: 37686880

Omega‑3 product improved knee pain/function and raised omega‑3 index; clinical benefit plausibly mediated by inflammation reduction.

PubMed ID: 23123043

Rapid incorporation of EPA/DHA into WBCs and prompt decrease in serum PGE2 in cancer patients — clear anti‑inflammatory signal.

PubMed ID: 29577973

High‑dose n‑3 in CKD robustly increased neutrophil pro‑resolving mediators and lowered plasma MPO — strong mechanistic anti‑inflammatory evidence.

PubMed ID: 25908532

High-quality RCT in CKD showed increased resolvin precursors (18-HEPE, 17-HDHA) and RvD1 after n-3 therapy — direct evidence of promoting resolution pathways.

PubMed ID: 27977757

NAFLD children had large histologic improvement (reflects reduced hepatic inflammation) with DHA+vitamin D.

PubMed ID: 14652498

Antioxidant product including DHA reduced exercise‑induced IL‑6 and CRP — inflammation attenuation observed.

PubMed ID: 25029008

28 days DHA reduced some IL‑6 and CK responses after eccentric exercise (biochemical inflammation reduction).

PubMed ID: 38589346

EPA/nano‑curcumin and combination reduced hs‑CRP in T2DM patients; inflammation markers improved.

PubMed ID: 2363736

Dose‑dependent reductions in neutrophil LTB4 and clinical RA signs indicate strong anti‑inflammatory action.

PubMed ID: 1464864

In RA, omega‑3s improved morning stiffness/global assessment — consistent with anti‑inflammatory benefit though confounded by NSAID co‑use.

PubMed ID: 8220938

Long‑term fish oil in RA permitted large NSAID reductions without worsening disease, indicating sustained anti‑inflammatory effect.

PubMed ID: 7918310

Large and sustained decreases in monocyte tissue factor activity and cellular incorporation of EPA/DHA indicate anti‑inflammatory/pro‑resolving actions.

PubMed ID: 8050452

Reduced CD25 expression on stimulated lymphocytes reflects decreased immune activation/inflammatory signaling in skin disease patients.

PubMed ID: 14583341

DHA reduced urinary F2-isoprostanes (~20%), a validated oxidative/inflammatory biomarker.

PubMed ID: 15458276

RA trial showed significant reductions in inflammatory biomarkers with n‑3 supplementation plus low n‑6 diet.

PubMed ID: 17720098

γ‑tocopherol+DHA lowered IL‑6 and WBC in dialysis patients—evidence of reduced systemic inflammation (combination therapy).

PubMed ID: 26226139

Fish oil reduced biomarkers linked to NAFLD and inflammation in adults—meaningful anti‑inflammatory evidence.

PubMed ID: 26078579

PUFA diet reduced inflammatory/oxidative markers and improved NASH histology—clear anti‑inflammatory signal.

PubMed ID: 23886520

Diet raising n-3 while lowering n-6 reduced headache frequency and increased DHA/EPA-derived pro-resolving mediators, indicating anti-inflammatory action.

PubMed ID: 34526307

Dietary EPA+DHA increased DHA‑derived oxylipins (17‑HDHA) and produced clinically meaningful reductions in migraine days/hours — strong anti‑inflammatory/functional signal.

PubMed ID: 40600308

High EPA+DHA/low‑LA diet raised plasma 17‑HDHA and reduced headache days/intensity in persistent post‑traumatic headache — clear link between DHA‑derived SPMs and symptom reduction.

PubMed ID: 12720588

Dose‑dependent suppression of stimulated IL‑6 production with fish oil indicates anti‑inflammatory action at the cellular level.

PubMed ID: 23332800

High‑dose marine n‑3 increased EPA/DHA and EPA-derived mediators and improved AA/EPA ratio with associated TAG/HDL improvements—anti‑inflammatory profile.

PubMed ID: 24121184

Perioperative fish‑oil raised EPA and was associated with reduced LTB4 and lower PCT—clear postoperative anti‑inflammatory signals.

PubMed ID: 24027184

Prospective association between higher dietary n‑3 intake and lower CRP 12 years later—population‑level evidence for inflammation reduction.

PubMed ID: 24553997

EPA+DHA reduced inflammatory and noninflammatory acne lesions and decreased IL‑8 staining—clinical anti‑inflammatory skin effect.

PubMed ID: 25240692

DHA‑enriched canola oil reduced IL1B expression and hs‑CRP and increased adiponectin in abdominal obesity—robust anti‑inflammatory/metabolic changes.

PubMed ID: 26378118

Parenteral ω‑3 in preterm infants raised EPA/DHA and significantly lowered IL‑6 and IL‑8—strong anti‑inflammatory evidence.

PubMed ID: 28287415

Ahiflower (SDA) increased anti‑inflammatory IL‑10 after stimulation—direct anti‑inflammatory signal.

PubMed ID: 30900815

EPA+DHA supplementation reduced inflammatory cytokine production (IL‑6) from immune cells.

PubMed ID: 32512364

Fatty fish or Camelina raised specialized anti‑inflammatory lipid mediators (e.g., 18‑HEPE, 17‑HDoHE).

PubMed ID: 34071714

n‑3 enriched eggs raised resolvins and modulated T cell cytokines (↓IL‑6) and Treg/Th17 distribution — mechanistic anti‑inflammatory evidence.

PubMed ID: 41373925

FFAR4 activation with correlated ↓TNF‑α and ↑IL‑10 demonstrates a mechanistic anti‑inflammatory pathway for marine n‑3s.

PubMed ID: 28343553

ALA + marine n‑3 with amitriptyline improved pain and pelvic‑floor tone — consistent with anti‑inflammatory/pain‑modulating effects.

PubMed ID: 7958682

Fish oil raised mucosal EPA/DHA, lowered AA and reduced abnormal rectal proliferation — anti‑inflammatory/anti‑proliferative biomarker effects.

PubMed ID: 8720373

Small RCT showing incorporation of n‑3 into gingival membranes and a significant reduction in gingival inflammation (Gingival Index).

PubMed ID: 9555791

IV omega-3 decreased psoriasis severity and shifted leukotriene/thromboxane generation toward less proinflammatory profiles (strong clinical anti-inflammatory effect).

PubMed ID: 15531659

RCT in Crohn's showed incorporation of EPA/DHA into immune cells and reductions in proinflammatory IFN-γ and PGE2 (direct anti-inflammatory evidence).

PubMed ID: 16437657

Omega‑3 reduced relapse in pediatric Crohn's and showed RBC EPA/DHA incorporation with decreased arachidonic acid—strong anti‑inflammatory signal.

PubMed ID: 18493214

AA+DHA shifted immune cell surface markers and cytokine‑related responses consistent with altered inflammatory potential.

PubMed ID: 19390480

Omega‑3 supplementation in pregnant women decreased LPS‑stimulated PGE2 secretion from whole blood—direct anti‑inflammatory signal.

PubMed ID: 21296957

Fish oil supplementation produced clear shifts in eicosanoid and specialized n‑3 metabolite levels (5‑HEPE, 15‑HEPE, 17‑HDoHE) — mechanistic anti‑inflammatory evidence.

PubMed ID: 23260750

IV n‑3 in critically ill patients lowered AA and altered n‑6:n‑3 ratio with associated physiological improvements — supports anti‑inflammatory action in severe illness.

PubMed ID: 22805468

Postnatal fish oil lowered Th2 cytokine IL‑13 and altered inflammatory cytokine responses—direct evidence of immune/inflammatory modulation.

PubMed ID: 24736647

Supplementation raised neutrophil electrophilic ω‑3 ketone derivatives (anti-inflammatory mediators) in RCT.

PubMed ID: 25926387

Higher circulating EPA/DHA strongly associated with substantially less intraprostatic inflammation (observational).

PubMed ID: 27637335

Rapid EPA/DHA incorporation and lowered AA/(EPA+DHA) ratio in sepsis implies anti‑inflammatory effects.

PubMed ID: 28302406

RA trial showed reduced joint counts and shifts away from 5‑LOX proinflammatory products toward DHA‑derived mediators.

PubMed ID: 34728723

Maternal algae‑DHA markedly raised breast‑milk DHA—biomarker plausibly supporting infant retinal/visual development though clinical outcomes not reported here.

PubMed ID: 35495419

Randomized AA+DHA supplementation halved the risk of severe retinopathy of prematurity (severe ROP) in extremely preterm infants—strong vision outcome evidence.

PubMed ID: 39702768

AA+DHA reduced treated/severe ROP incidence (~50% relative reduction) and altered platelet‑related pathways—robust neonatal vision benefit.

PubMed ID: 33339438

Maternal MMS increased milk DHA — DHA is a key retinal omega‑3 and increased milk DHA supports infant retinal DHA supply.

PubMed ID: 8541278

Third‑trimester fish oil increased neonatal DHA in umbilical plasma/vessel walls—biochemical substrate important for retinal/visual development.

PubMed ID: 8949693

DHA-containing feeds accelerated visual evoked potential maturation in preterm infants (supportive for vision development).

PubMed ID: 11864865

Randomized trial: LCP (including DHA) improved infant visual acuity and stereoacuity (strong functional vision evidence).

PubMed ID: 15364709

Subgroup analyses in RP trial showed DHA slowed some vision decline for ~2 years in those not on prior vitamin A and higher DHA associated with slower decline.

PubMed ID: 15333721

DHA‑enriched baby food increased RBC DHA and improved visual acuity (~1.5 lines) at 12 months — robust infant vision benefit.

PubMed ID: 17393217

Maternal DHA modestly improved infant visual acuity at 4 months (RCT), a direct vision benefit.

PubMed ID: 18469279

DHA (±lutein) increased macular pigment optical density at some retinal loci in older women.

PubMed ID: 18446020

200 mg/day maternal DHA doubled breast‑milk DHA and raised infant RBC‑DHA—strong biological plausibility for supporting infant visual development.

PubMed ID: 18326591

Maternal 400 mg/day DHA was associated with higher odds of better infant visual acuity at 60 days—direct visual benefit.

PubMed ID: 21531481

90-day DHA supplementation raised omega-3 biomarkers and produced a measurable improvement in right-eye visual acuity in older adults (small trial).

PubMed ID: 21402976

Large prospective cohort showed substantially lower risk (~35–45%) of vision-threatening AMD with higher dietary DHA/EPA and fish intake—strong observational support.

PubMed ID: 22332205

Large pooled dataset: higher dietary long‑chain n‑3 (mainly DHA) intake linked to substantially slower central visual acuity and field loss in retinitis pigmentosa.

PubMed ID: 23434908

One-year lutein + DHA increased macular pigment optical density in early AMD patients, although short-term vision tests did not change.

PubMed ID: 23519529

Lutein/zeaxanthin + ω‑3 supplementation increased macular pigment optical density and plasma antioxidants over 12 months in nonexudative AMD patients (direct support for retinal health).

PubMed ID: 23642375

EPA+DHA improved tear film stability and symptoms in dry‑eye disease, supporting ocular surface health relevant to vision comfort.

PubMed ID: 23963690

In very low birth weight infants parenteral fish‑oil (DHA) markedly reduced retinopathy of prematurity requiring treatment (large clinical vision benefit).

PubMed ID: 24557349

Higher circulating EPA (and EPA+DHA) strongly associated with much lower odds of neovascular AMD (case-control analysis).

PubMed ID: 25089351

Omega‑3 supplementation in anti‑VEGF‑treated wet AMD lowered vitreous VEGF‑A (local biological effect relevant to vision).

PubMed ID: 26469750

In X‑linked retinitis pigmentosa DHA raised RBC‑DHA and slowed visual field loss correlated with blood DHA (strong vision‑preserving signal in adherent subjects).

PubMed ID: 26132079

DHA showed genotype‑specific protection against incident CNV in CFH non‑risk homozygotes (AMD‑related vision benefit in a subset).

PubMed ID: 25697893

Oral EPA+DHA halved dry‑eye symptom scores and improved tear breakup time and Schirmer test (clinically meaningful ocular surface benefits).

PubMed ID: 26322917

Large randomized double‑blind trial: high‑dose omega‑3 improved dry‑eye symptoms and tear film stability in screen users.

PubMed ID: 27817918

Krill and fish oil improved tear stability and osmolarity; krill oil also reduced symptoms and tear IL‑17A.

PubMed ID: 27442314

Well‑powered RCT: re‑esterified EPA+DHA substantially improved signs and symptoms of dry eye and reduced tear osmolarity/MMP‑9.

PubMed ID: 27787443

High‑DHA oral supplements added to ranibizumab reduced macular thickness in diabetic macular edema (anatomical visual benefit).

PubMed ID: 30614004

Enteral DHA in very low‑birth‑weight preterms reduced risk of severe (stage 3) retinopathy of prematurity.

PubMed ID: 31963702

Microencapsulated tuna oil in toddler formula produced larger increases in blood DHA and omega‑3 index — biomarker relevant to visual development/retina.

PubMed ID: 32544914

Lutein + DHA increased macular pigment optical density far more than lutein alone — strong supportive evidence for retinal nutrient status.

PubMed ID: 34882608

EPA+DHA+GLA produced clinically meaningful improvements in very symptomatic dry‑eye patients (ocular surface outcome related to vision comfort).

PubMed ID: 37026312

Large RCT in digital‑display users showed RBC omega‑3 index increased and clinically meaningful improvements in multiple dry‑eye clinical endpoints (TBUT, Schirmer, osmolarity).

PubMed ID: 36904299

Keratoconus patients showed reduced ocular oxidative/inflammatory markers after high‑dose DHA, relevant to corneal health/vision.

PubMed ID: 38753336

Dry‑eye/meibomian gland dysfunction study showed improved tear stability and eyelid signs, relevant to ocular surface/vision comfort.

PubMed ID: 40791013

800 mg/day prenatal DHA was linked to faster infant visual learning and more mature attention — direct visual development support.

PubMed ID: 24427279

Maternal 400 mg/day DHA reduced risk of infants scoring outside top performers for early visual acuity at 2 months.

PubMed ID: 32858063

Large AREDS/AREDS2 cohort data: higher dietary long‑chain omega‑3 intake linked to lower progression to late AMD (strong observational evidence).

PubMed ID: 1386065

VLBW infants receiving long‑chain n‑3 (DHA) showed preserved/improved rod retinal function versus deficient formula — strong functional vision evidence.

PubMed ID: 8615350

Preterm infants fed marine n‑3 LCPUFAs had early visual acuity improvement (2‑month outcome) in certain infants—direct vision benefit.

PubMed ID: 10443966

Cheek cell DHA strongly correlated with VEP acuity and other visual measures in preterm infants—good tissue/functional correlation.

PubMed ID: 11528489

Preterm infants show substantial absorption/retention of supplemented DHA—important for retinal/visual development.

PubMed ID: 16540798

Higher‑DHA formula raised infant RBC DHA markedly—supports substrate availability for visual development.

PubMed ID: 22008957

Dose‑dependent formula DHA increased infant plasma/erythrocyte DHA to levels comparable to human milk (biomarker important for vision development).

PubMed ID: 28271618

Higher plasma DPA was cross‑sectionally associated with greater central macular pigment density (observational association).

PubMed ID: 29843467

Fortifier increased infant RBC/plasma DHA and EPA—nutrient increases relevant to retinal development and vision.

PubMed ID: 37892412

Maternal fish consumption and breastfeeding were associated with higher infant serum DHA — infant DHA supports visual development.

PubMed ID: 8726246

Term infants given DHA+AA formula had improved early grating visual acuity and increased blood DHA/AA.

PubMed ID: 8958000

Supplementing preterm formula with DHA raised infant DHA to breast‑fed levels—biochemical change associated with visual development.

PubMed ID: 9702915

Same as above (strong trial-level evidence for improved visual evoked acuity).

PubMed ID: 9552137

DHA-supplemented formulas raised infant RBC DHA to breast-fed levels; visual acuity differences were small/inconclusive but biomarker-normalizing.

PubMed ID: 10755457

DHA+AA in infant formula correlated with RBC/plasma DHA and improved Bayley MDI; visual acuity/correlations reported supporting vision benefit.

PubMed ID: 11144440

DHA‑enriched formula matched breastfed DHA and produced more mature ERG responses and better visual acuity at 17 and 52 weeks.

PubMed ID: 10653329

High‑DHA formula maintained DHA in term infants but lowered AA; biochemical maintenance relevant for vision though tradeoffs noted.

PubMed ID: 11483801

Large RCT in preterms: AA+DHA improved VEP acuity toward breastfed reference and supported visual maturation.

PubMed ID: 12139873

Formulas lacking omega‑3/omega‑6 produced lower RBC DHA/ARA vs breastfed infants, supporting DHA importance for retinal/visual status.

PubMed ID: 12838196

Term infants supplemented with DHA+ARA had higher RBC‑DHA and significantly improved VEP visual acuity at 1 year—strong functional vision evidence.

PubMed ID: 15817866

Term infants fed DHA+ARA had significantly better sweep VEP acuity across the first year and higher RBC DHA (robust vision benefit).

PubMed ID: 16483397

DHA prevented large declines in erythrocyte DHA in PKU infants and may aid visual maturation.

PubMed ID: 17185423

Maternal fish oil improved eye–hand coordination (sensorimotor/visual integration), though not a direct acuity measure.

PubMed ID: 17240089

DHA/ARA‑supplemented infant formula produced visual acuity at age 4 similar to breast‑fed children (benefit for vision development).

PubMed ID: 18842793

Preterm infants given higher DHA dose had significantly better VEP visual acuity at 4 months.

PubMed ID: 20130095

Large double‑masked RCT found clear, clinically meaningful improvement in infant VEP visual acuity with DHA supplementation.

PubMed ID: 26015389

ω‑3 enriched eggs raised RBC DHA and produced a significant improvement in distance visual acuity in children.

PubMed ID: 27391868

Higher‑DHA infant formulas raised RBC DHA to levels similar to breastfed infants — DHA status relevant to visual development.

PubMed ID: 27571269

Infant formula with DHA/ARA raised DHA‑containing plasma phospholipids to levels similar to breast milk—important for vision development.

PubMed ID: 31371795

SQ‑LNS‑plus raised plasma DHA at 12 months, lowering n‑6:n‑3 ratio—biomarker changes supportive of visual development.

PubMed ID: 33523106

Large RCT in extremely preterm infants halved severe ROP incidence with enteral AA+DHA and raised circulating AA/DHA—strong vision‑specific clinical effect.

PubMed ID: 33358843

High‑dose enteral DHA+ARA quickly raised whole‑blood DHA and ARA (dose responsiveness relevant to retinal development).

PubMed ID: 24568073

ADHD trial: behavior and hyperactivity improvements with EPA+DHA may reflect better neurobehavioral function.

PubMed ID: 32121236

Omega‑3 (±vitamin D) improved some social/communication scores in ASD children with elevated IL‑1β — domain‑specific brain/behavioral benefit in a subgroup.

PubMed ID: 34999335

24‑month trial showed improved working memory along with increases in plasma ω‑3FA and tissue carotenoids.

PubMed ID: 33675344

High‑dose EPA+DHA improved multiple cognitive domains (language, memory, visual‑motor) in older adults with coronary disease over 12–30 months.

PubMed ID: 34113957

Well‑powered RCT: EPA‑rich oil improved overall cognitive accuracy and speed in healthy young adults; DHA had smaller effects — strong cognitive signal.

PubMed ID: 33749643

DHA (with folic acid) improved specific cognitive tests and reduced blood amyloid‑β in older adults with MCI — supportive of brain health.

PubMed ID: 34543890

Prenatal DHA produced genotype‑dependent improvements in child cognitive domains at age 5 → developmental brain function benefit.

PubMed ID: 34214231

Fish‑oil changed corticolimbic connectivity; connectivity changes correlated with depressive symptom improvements (neural‑mechanistic brain effect).

PubMed ID: 34139404

Fish‑oil improved brain network measures (fMRI) and produced symptom improvements in depressed youth — objective brain function changes.

PubMed ID: 35722886

Pilot DHA in concussed adolescent athletes trended toward faster symptom resolution and earlier return‑to‑sport (brain recovery signals, albeit underpowered).

PubMed ID: 35644107

Omega‑3/6/9 in preterm toddlers improved caregiver‑reported interpersonal and internalizing domains (behavioral brain/psychiatric outcomes).

PubMed ID: 35704085

Higher baseline plasma DHA predicted greater 2‑year cognitive benefit from B‑vitamins—supports DHA role in brain function and cognition.

PubMed ID: 37651975

DHA added to piracetam in children with breath‑holding spells markedly reduced frequency/severity — neurologic/brain effect.

PubMed ID: 37294565

High‑dose neonatal DHA increased full‑scale IQ in extremely preterm infants — clear cognitive/brain function benefit.

PubMed ID: 38680033

In newborns with hyperbilirubinemia, DHA reduced NSE and abnormal MRIs, indicating neuroprotective/brain benefits.

PubMed ID: 38952108

DHA (800 mg) improved cognitive test scores and reduced oxidative DNA damage in older adults with MCI.

PubMed ID: 38244783

Add‑on EPA+DHA improved immediate memory in depressed adults — evidence of cognitive function benefit in adults.

PubMed ID: 40791013

Higher prenatal DHA improved infant visual learning and attention maturation — direct early brain function measures.

PubMed ID: 18519483

Very preterm infants showed better problem‑solving scores and ERP markers of recognition memory after DHA+ARA supplementation.

PubMed ID: 19201180

Schoolchildren with increased blood DHA/EPA improved multiple cognitive measures (memory/spelling), reflecting enhanced brain function.

PubMed ID: 20130095

Large RCT showed that infant formula DHA improved visual development at 12 months—a key neural/visual functional outcome.

PubMed ID: 20624152

VLBW infant RCT: DHA+ARA improved sustained attention at 20 months and plasma DHA correlated with attention—direct functional CNS benefit.

PubMed ID: 21295417

Infant RCT: pooled DHA doses produced a modest but statistically significant increase in MDI at 18 months (direct cognitive endpoint).

PubMed ID: 23803884

Infant LCPUFA supplementation produced later improvements (ages 3–6) in executive and language measures—relevant to brain function.

PubMed ID: 23783296

Infant LC‑PUFA formula led to faster processing speed at 6 y (persistent domain‑specific cognitive benefit).

PubMed ID: 24958525

ADHD RCT produced working memory improvement with increased erythrocyte EPA/DHA, supporting a brain‑function benefit.

PubMed ID: 26424477

Higher AA:DHA formula in very preterm infants led to better psychomotor development at age 2 (developmental brain function).

PubMed ID: 25891115

Objective improvement in P300 latency indicates enhanced cognitive processing after low-dose LCPUFA supplementation.

PubMed ID: 27571269

Infant DHA/ARA enrichment raised brain‑relevant phospholipids supporting brain development.

PubMed ID: 27747986

LCPUFA in infancy produced stronger ERP indices of attention/inhibition—neural function evidence.

PubMed ID: 30392581

Maternal DHA+ARA increased newborn brain volumes (notably males)—structural brain function relevance.

PubMed ID: 30311214

Long‑term neuroimaging demonstrated durable functional, connectivity and structural brain differences from infant LCPUFA exposure.

PubMed ID: 19765006

Pooled RCT evidence of improved problem solving and intention in infants fed LCPUFA‑supplemented formula.

PubMed ID: 32116250

Link between DHA/AA increases with supplementation and reduced hippocampal atrophy supports preserved brain function.

PubMed ID: 33396458

Maternal AA/DHA predicted faster child processing speed to age 9 (longitudinal cognitive association).

PubMed ID: 32737350

Older adults showed modest improvements in attention and working memory with fish oil.

PubMed ID: 33444934

Adjunctive fish oil improved social cognition in recent‑onset psychosis (small RCT), supporting domain‑specific brain functional benefit.

PubMed ID: 38061271

Double‑blind RCT: ARA+DHA improved white‑matter microstructural maturation in very preterm infants—direct mechanistic evidence for brain development/function.

PubMed ID: 37447152

Memory improvements in older adults with baseline cognitive decline after EPA/DHA + lutein indicate clinical brain function benefits in at‑risk populations.

PubMed ID: 37513559

Higher PUFA (including DHA) intake during complementary feeding associated with better Bayley cognitive scores at 12 months in VLBW infants.

PubMed ID: 33339438

Maternal MMS including DHA significantly raised breast‑milk DHA — relevant to infant brain nutrient supply and development.

PubMed ID: 40044083

Large RCT in MCI found DHA (and MCT) improved global cognitive scores and related biomarkers—good evidence for brain-function benefit in MCI.

PubMed ID: 26213579

Fortasyn Connect trials (contain DHA) reliably raised DHA/EPA and lowered homocysteine — biomarker and mechanistic support for brain-target engagement.

PubMed ID: 31616139

Prodromal AD trial showed slower clinical decline and less hippocampal atrophy with Fortasyn Connect (with DHA), indicating structural/clinical brain benefits.

PubMed ID: 33097947

Fish oil improved task‑related cerebrovascular responsiveness and processing speed in males—functional brain effect.

PubMed ID: 11916764

Lactating mothers' DHA supplementation raised plasma and milk DHA, increasing substrate for infant brain development.

PubMed ID: 15333721

DHA‑enriched infant food increased RBC DHA and produced a clinically meaningful improvement in visual cortical function (VEP) by 12 months.

PubMed ID: 17490978

Maternal fish oil increased maternal and cord DHA, supporting fetal brain DHA delivery (biomarker for brain development).

PubMed ID: 17957152

Maternal fish oil raised milk and infant DHA and was associated with some developmental score improvements — supports early brain development.

PubMed ID: 18510807

DHA (with/without lutein) improved verbal fluency and some memory measures in older women (small RCT).

PubMed ID: 18446020

Maternal 200 mg/day DHA increased maternal, breast‑milk and infant RBC‑DHA—biomarker evidence supporting infant brain development.

PubMed ID: 18469236

Inattentive children had improved sustained attention with EPA/DHA (phospholipid form showing strongest effect).

PubMed ID: 20434961

DHA improved specific cognitive tests (learning/recognition) in older adults (randomized evidence for brain function).

PubMed ID: 20130094

Dose‑dependent increases in brain DHA coupled with fMRI activation changes during attention tasks (direct neural function evidence).

PubMed ID: 21929835

Randomized trial in MCI showed mood improvement and a DHA-related improvement in verbal fluency—evidence of domain-specific brain-function benefit.

PubMed ID: 22020134

DHA-rich fish oil increased task-related prefrontal hemodynamics—physiologic support for brain activation though limited performance gains.

PubMed ID: 17185423

Maternal high‑dose fish oil led to better eye–hand coordination at 2.5 years, an indicator of neurodevelopmental benefit.

PubMed ID: 16483397

In PKU infants DHA supplementation largely prevented DHA decline and may have supported visual (neural) maturation—strong physiological neurodevelopment evidence.

PubMed ID: 15812447

Preterm infants fed DHA+ARA formulas had better Bayley developmental scores—supports early brain development/function.

PubMed ID: 15069395

Preterm LCPUFA supplementation improved cognitive outcomes (notably in boys)—clinical developmental benefit.

PubMed ID: 12838196

DHA+ARA in term infants increased RBC‑DHA and improved visual cortical maturation (VEP)—neurodevelopmental functional evidence.

PubMed ID: 11483801

Large multicenter RCT in preterms showed improved electrophysiological vision and motor development with AA+DHA (neurodevelopmental benefit).

PubMed ID: 11144440

DHA‑enriched formula produced breastfed‑like RBC DHA and better electrophysiologic visual function—evidence of neural/retinal maturation.

PubMed ID: 10755457

DHA+AA in infant formula raised Bayley MDI (~+7 points) indicating improved early brain development.

PubMed ID: 9702915

Dietary DHA normalized RBC lipids and improved visual evoked acuity at several time points — VEP is a brain/visual pathway functional measure.

PubMed ID: 8958000

Preterm infant formula with DHA/AA raised blood LCPUFA to levels similar to breast-fed infants—biochemical support for brain substrate availability.

PubMed ID: 7478826

LC‑PUFA supplementation improved early neurodevelopmental scores (direct functional brain outcome in infants).

PubMed ID: 35171190

1‑year combination raising RBC DHA improved cognitive index and increased BDNF in healthy elderly — supports brain function.

PubMed ID: 36418565

250 mg algal DHA doubled serum DHA in vegans and raised DHA/AA ratio — demonstrates bioavailability needed for brain DHA support.

PubMed ID: 29843467

Fortifier supplying preformed DHA increased infant plasma/RBC DHA—biomarker important for early brain development/function.

PubMed ID: 25585167

EPA+DHA reduced transition to psychosis and improved functioning in ultra‑high risk individuals—strong clinically relevant brain/psychiatric benefit.

PubMed ID: 26169870

Infant salmon feeding significantly increased infant EPA/DHA—directly relevant to brain development/function.

PubMed ID: 12509593

Maternal DHA supplementation led to modest but significant cognitive improvements in offspring at age 4—strong developmental brain evidence.

PubMed ID: 11972740

Lower infant DHA status associated with poorer neurodevelopmental scores at 1 year—strong relevance to early brain development/function.

PubMed ID: 40412614

Maternal higher DHA associated with differences in infant ERP/EEG measures at 1 and 6 months, consistent with altered early brain processing.

PubMed ID: 28747210

Souvenaid produced rapid MRS changes in brain phospholipid metabolism—mechanistic support for improved brain function.

PubMed ID: 24475144

Souvenaid (contains DHA) preserved functional brain network organization over 24 weeks in mild AD (robust RCT evidence).

PubMed ID: 22932777

Memory improvements in MCI after concentrated DHA indicate functional brain benefits in older adults (12‑month RCT, small sample).

PubMed ID: 22348468

High‑dose infant fish oil raised DHA and produced modest improvements in early communicative gestures (developmental/brain function signal).

PubMed ID: 22234041

n‑3 containing oral supplement improved cognitive function subscale and global QoL in lung cancer patients, supporting brain functional benefit in this context.

PubMed ID: 24214970

Higher erythrocyte EPA+DHA associated with better attention, behavior and spelling in children with ADHD—associative evidence for cognitive/brain function.

PubMed ID: 23433688

Maternal DHA (600 mg/day) increased fetal HRV and improved newborn neurobehavior on the NBAS, indicating effects on neurobehavioral maturation.

PubMed ID: 23515006

DHA improved cognitive processing speed and memory reaction times in a randomized trial—direct evidence of enhanced brain function in young adults.

PubMed ID: 24098072

Krill/sardine oil increased task‑related prefrontal activation and shortened P300 latency—physiologic markers of improved cortical processing in older adults.

PubMed ID: 24410954

Supplementation increased CSF EPA/DHA and CSF DHA changes correlated with Alzheimer's biomarkers, indicating central nervous system bioavailability and biomarker modulation.

PubMed ID: 24508294

Improved processing speed, attention/executive function and other cognitive domains in malnourished children (RCT).

PubMed ID: 25877495

Omega‑3 status modified B‑vitamin effect on brain atrophy in MCI—strong implication for brain preservation/function.

PubMed ID: 26679763

Adjunct n‑3 PUFA improved PANSS scores and depressive symptoms in schizophrenia, indicating functional brain/psychiatric benefits.

PubMed ID: 27362506

Prenatal DHA improved infant sustained attention across 4–9 months, indicating early brain function/performance benefits.

PubMed ID: 26765633

Dose‑dependent DHA increases associated with reduced serum NFL across a season—biomarker evidence of neural protection.

PubMed ID: 27604770

Prenatal DHA improved sustained attention at age 5 (cognitive function outcome).

PubMed ID: 27358067

Oral DHA markedly increased plasma and modestly increased CSF DHA—direct evidence of CNS delivery potential.

PubMed ID: 26757190

Higher baseline DHA/EPA status enhanced cognitive benefit from B‑vitamins in MCI—supports DHA relevance to brain function.

PubMed ID: 26890759

High‑dose omega‑3 improved spatial memory in healthy older adults and raised omega‑3 index—functional brain benefit.

PubMed ID: 27716665

DHA improved cognitive test scores and preserved hippocampal volume in MCI over 12 months—strong neuroprotective/function evidence.

PubMed ID: 28075381

Robust cognitive domain improvements in older adults with MCI indicate clear brain‑function benefits.

PubMed ID: 29097166

Slowed clinical decline and reduced hippocampal atrophy in prodromal AD indicate brain‑protective effects.

PubMed ID: 28651701

Oxidative stress reductions correlated with symptom improvements in schizophrenia (biomarker→clinical brain effects).

PubMed ID: 29142143

24‑month DHA RCT in MCI improved multiple cognitive domains and altered Aβ/autophagy biomarkers—strong evidence for brain function benefits.

PubMed ID: 28527220

Higher erythrocyte EPA+DHA associated with greater regional cerebral perfusion and a cognitive subscore—supportive cross‑sectional evidence.

PubMed ID: 29098783

In Malawian mothers, higher breastmilk DHA was linked to small benefits in infant attention and verbal function—relevant to early brain development/function.

PubMed ID: 30170260

Year‑long EPA/DHA reduced seizure frequency substantially in drug‑resistant epilepsy—direct neurologic benefit.

PubMed ID: 29530020

Fatty‑fish lunches in children raised EPA/DHA and yielded small improvements in processing speed and fine motor performance — brain function domains.

PubMed ID: 31030946

ELBW infants receiving fish‑oil containing parenteral lipid reached electrophysiological brain maturation ~2 weeks earlier — robust neonatal brain function outcome.

PubMed ID: 31345172

Fortasyn Connect (includes DHA) slowed cognitive worsening in prodromal AD and indirectly reduced dementia risk — relevant to brain function preservation.

PubMed ID: 30958356

Omega‑3 produced cognitive benefits in Alzheimer's subgroup with lower homocysteine — suggests brain benefit dependent on nutritional context.

PubMed ID: 32690472

High‑dose DHA increased CSF DHA and plasma DHA in older adults—direct evidence of brain delivery relevant to brain function.

PubMed ID: 32856190

DHA ± folic acid improved cognitive scores in MCI, indicating functional brain benefits.

PubMed ID: 33221631

Fish‑oil adjunct preserved white‑matter microstructure and prevented antipsychotic‑associated deterioration—neurobiological brain protection.

PubMed ID: 31991898

Large randomized trial in MCI adults showed robust improvements in global cognition and functional measures with high‑dose ω‑3/ω‑6+antioxidant.

PubMed ID: 28029926

Large RCT: maternal fish‑oil reduced persistent wheeze/asthma and LRTIs in offspring—clinical immune outcome.

PubMed ID: 29031393

Maternal DHA shifted maternal/infant cytokines toward a less inflammatory profile (reduced infant TNF-α).

PubMed ID: 29061183

Preoperative EPA+DHA prevented rises in hsCRP and CD4+ loss vs placebo, indicating immune stabilization.

PubMed ID: 12720588

Fish oil reduced stimulated IL‑6 production in healthy adults—direct immunomodulatory evidence.

PubMed ID: 25039804

Infant supplementation increased RBC DHA and produced modest, time‑limited reductions in stimulated inflammatory cytokines (IL‑1β/TNFα) in at‑risk infants.

PubMed ID: 24970858

Adjunct DHA reduced local inflammatory markers (crevicular fluid hsCRP, IL‑1β) and periodontal pocket depth—direct local immune/inflammatory benefit.

PubMed ID: 23531329

Prenatal EPA/DHA changed cord‑blood chemokine ratios (less Th2 bias), indicating fetal immune modulation.

PubMed ID: 22294737

Prenatal n‑3 LCPUFA reduced atopic eczema and egg sensitisation in infants (immune/allergic outcomes).

PubMed ID: 22929118

Large changes in blood gene‑expression (many immune genes) after fish oil, indicating immune pathway modulation.

PubMed ID: 23023905

8‑week trial in T2D lowered pro‑inflammatory cytokines (TNF‑α, IL‑2), supporting immune/inflammation effects.

PubMed ID: 22285316

Small CKD study showed a modest but significant IL‑1β decrease, indicating some immune modulation.

PubMed ID: 21941411

Randomized maternal DHA produced large, statistically significant changes in infant lymphocyte subsets and marked IFN-γ suppression—direct immune modulation.

PubMed ID: 21332799

Maternal EPA+DHA supplementation in an RCT substantially reduced IgE-associated allergic disease in offspring to age 2 (clinically meaningful immune outcome).

PubMed ID: 22160495

Low-dose fish oil during chemotherapy preserved neutrophil counts and function (phagocytosis, superoxide) and prevented weight loss—supports immune competence.

PubMed ID: 22079797

Oral DHA during neonatal sepsis lowered IL‑1β and raised leukocyte DHA — supportive immune effect.

PubMed ID: 22136963

Infant lipid emulsion RCT markedly reduced TNF-α and was linked to milder illness — clear immune effect.

PubMed ID: 21807696

Prenatal DHA reduced some infant cold symptoms and shortened several illness durations in early infancy (mixed effects but supportive of immune benefit).

PubMed ID: 20545703

EPA‑enriched nutritional formula reduced airway inflammation (FeNO) and improved bronchial responsiveness in children with asthma (small RCT).

PubMed ID: 19489765

Maternal EPA+DHA supplementation markedly reduced food allergy and IgE‑associated eczema in high‑risk infants (strong RCT clinical immune outcome).

PubMed ID: 19515734

PBMC gene expression shifted toward anti‑inflammatory/anti‑atherogenic profiles after 6 months EPA+DHA (direct immune-cell molecular effects).

PubMed ID: 19158225

3 g/day DHA reduced neutrophils and systemic inflammatory markers (CRP, IL‑6), indicating immune modulation in hypertriglyceridemic men.

PubMed ID: 18930251

RCT in children showed fewer and shorter infectious illnesses with fish oil, strong clinical immune benefit.

PubMed ID: 2363736

Dose-dependent reductions in neutrophil LTB4 and joint signs indicate immuno-inflammatory modulation.

PubMed ID: 8220938

Long‑term fish oil in RA allowed marked NSAID reduction without worsening — consistent with anti‑inflammatory/immunomodulatory benefit.

PubMed ID: 15051614

DHA reduced T‑lymphocyte activation (CD69) in healthy adults — direct immunomodulatory effect.

PubMed ID: 16943451

Elderly trial showed improved delayed‑type hypersensitivity and PBMC proliferation with fish oil+vitamin E (direct immune markers).

PubMed ID: 17391558

DHA lowered neutrophil oxidative activity and preserved bactericidal function with exercise — supports immune function modulation.

PubMed ID: 17875549

Fish oil improved lupus activity and endothelial biomarkers, implying immune‑mediated disease benefit.

PubMed ID: 17980419

Prenatal fish oil altered fetal/maternal cytokine mRNA (lower TH2, higher TGF-β), showing immunomodulation.

PubMed ID: 40644954

Combined n‑3+micronutrient trial in older adults lowered an aggregated INFLA score (modest systemic immune/inflammation benefit).

PubMed ID: 40126831

Maternal DHA modestly reduced early infant respiratory symptoms and some infections, supporting immune protection in infants.

PubMed ID: 38518540

Year‑long 1 g/day EPA+DHA reduced pro‑inflammatory eicosanoids and increased pro‑resolving substrates — supports immune/inflammatory modulation.

PubMed ID: 39275147

Combined EPA/DHA product reduced eczema severity and steroid need, implying immune/atopic benefit (combination product).

PubMed ID: 36074245

Prenatal DHA modified/attenuated arsenic‑associated increased risk of atopic dermatitis (immune/allergic outcome).

PubMed ID: 34516692

In small COVID RCT, added DHA/EPA produced faster symptom improvement and favorable inflammatory marker changes (supports immune recovery).

PubMed ID: 34578993

Raised EPA/DHA in PBMCs and produced large, oil‑dependent changes in T‑cell activation transcriptome → direct mechanistic immunomodulation.

PubMed ID: 34959801

1000 mg DHA/day altered maternal immune markers (sRAGE, IL‑6) and reduced preterm birth risk, indicating immune‑mediated effects in pregnancy.

PubMed ID: 33812168

EPA reduced vascular inflammatory gene expression (CCL2) in humans and mice → relevant to immune/inflammatory pathways.

PubMed ID: 32044905

In hypertensive adults, fish oil raised omega‑3 and significantly lowered inflammatory cytokines (TNF‑α) and CRP, reflecting immune/inflammatory modulation.

PubMed ID: 29940888

Prenatal EPA‑rich (contrast relevant) reduced maternal IL‑6, TNFα and IL‑15 — direct cytokine reductions supportive of immune effects.

PubMed ID: 29385062

RCT in gestational diabetes showed downregulation of IL-1 and TNF‑α and upregulation of PPAR‑γ indicating clear anti‑inflammatory/immune modulation.

PubMed ID: 29735019

High‑dose EPA+DHA reduced circulating proinflammatory cytokines in older adults with chronic wounds, supporting immune/inflammatory regulation.

PubMed ID: 29195133

Pilot RCT showed DHA-rich fish oil altered B-cell cytokine responses and reduced ex vivo IgM production, indicating immunomodulation.

PubMed ID: 28987470

High‑dose omega‑3 in Duchenne boys reduced pro‑inflammatory cytokines and increased anti‑inflammatory IL‑10 (immune modulation).

PubMed ID: 29173199

Prenatal n‑3 increased pro‑resolving mediator precursors in cord blood, showing immune/resolution pathway effects at birth.

PubMed ID: 22009072

Large randomized schoolfood trial: higher n‑3 intake reduced frequency and duration of respiratory/GI illnesses in children.

PubMed ID: 24121184

Infant perioperative fish‑oil raised EPA and reduced proinflammatory/procalcitonin markers, suggesting enhanced immune/inflammatory control.

PubMed ID: 26378118

ω‑3 IV lipid in preterm neonates raised EPA/DHA and lowered IL‑6/IL‑8, indicating direct immune/inflammatory modulation.

PubMed ID: 28287415

Ahiflower (SDA) raised LPS‑stimulated IL‑10 (~45%), indicating an anti‑inflammatory/immune‑modulating effect.

PubMed ID: 34071714

n‑3 enriched eggs raised pro‑resolving mediators (RvE1), increased TGF‑β1 and lowered IL‑6 — direct immune/resolution signaling changes.

PubMed ID: 41373925

Marine EPA/DHA increased PBMC FFAR4 activation and correlated with lower TNF‑α and higher IL‑10 — clear anti‑inflammatory/immune modulation.

PubMed ID: 9555791

IV omega-3 altered inflammatory eicosanoids and reduced psoriasis severity (clinically relevant immune/inflammatory effect).

PubMed ID: 15531659

RCT in Crohn's showed EPA/DHA incorporation into immune cells with reduced IFN-γ and PGE2 (direct immune modulation).

PubMed ID: 15298564

Maternal fish-oil raised breast-milk DHA/EPA and these n-3 levels correlated with IgA/sCD14 (biomarker links to immunity).

PubMed ID: 16437657

Omega‑3 (including DHA) added to therapy significantly reduced 1‑yr relapse rate in pediatric Crohn's and raised blood EPA/DHA.

PubMed ID: 18493214

Long‑term AA+DHA changed several T/B/macrophage surface markers in children, indicating immune phenotype modulation.

PubMed ID: 19390480

Maternal omega‑3 supplementation raised EPA/DHA and significantly reduced LPS‑induced whole‑blood PGE2 (an inflammatory/immune mediator).

PubMed ID: 20227721

Infant RCT: DHA/ARA formula substantially reduced respiratory infections, wheeze and allergies through age 3.

PubMed ID: 22805468

Large RCT in infants: fish oil raised DHA/EPA and shifted immune markers (↓IL‑13, ↑IFNγ/TNF), indicating immune modulation.

PubMed ID: 24736647

Supplementation increased neutrophil production of anti-inflammatory electrophilic ω‑3 metabolites, supporting immune-modulatory effects.

PubMed ID: 27637335

Septic ICU study: rapid EPA/DHA incorporation and trends toward improved survival (immune modulation).

PubMed ID: 26970335

Maternal supplementation raised milk EPA/DHA and reduced IgE-associated infant allergy (immune outcome).

PubMed ID: 28302406

RA RCT showed shift toward anti‑inflammatory lipid mediators (and clinical disease‑activity reductions), supporting immune modulation.

PubMed ID: 40651709

RCT showed DHA increased IFN-γ/TNF-α and oxylipins indicating immune modulation though no change in tumor-infiltrating lymphocytes.

PubMed ID: 40405290

High‑dose DHA during chemotherapy preserved NLR, monocyte HLA‑DR and ex vivo cytokine responses, indicating preserved immune function.

PubMed ID: 27276431

Infant formula trial showed changes in lymphocyte ARA and B‑cell activation marker (immune‑related).

PubMed ID: 31006007

Dose‑dependent rises in EPA/DHA‑derived oxylipins and SPM precursors indicate strong mechanistic immune/anti‑inflammatory effects.

PubMed ID: 33041091

Post‑AMI ω‑3 increased DHA/EPA oxylipins and decreased proinflammatory eicosanoids (PV evidence of immunomodulation).

PubMed ID: 36615804

Infant formula with higher DHA/ARA linked to fewer atopic/respiratory events vs standard formula—clinical immune‑related outcome.

PubMed ID: 37121228

ARA+DHA reduced IL‑6 and other proinflammatory cytokines in very preterm infants—direct anti‑inflammatory/immune modulation signal.

PubMed ID: 7874893

Large ICU RCT with fish‑oil formula showed fewer infections and shorter LOS (especially in septic subgroup).

PubMed ID: 10593328

Perioperative immunonutrition containing fish‑oil omega‑3s reduced postoperative infectious complications.

PubMed ID: 27126710

Tube‑feed RCT showed reduced diarrhea incidence — clinically relevant gut/immune protection signal.

PubMed ID: 26920136

Randomized pediatric trial with fortified milk (including DHA) showed fewer allergic manifestations — supports immune/allergic benefit though product had multiple actives.

PubMed ID: 29577973

High‑dose n‑3 in CKD increased pro‑resolving mediators and lowered MPO — biologically supportive of improved immune resolution.

PubMed ID: 27007392

n‑3 lowered oxidative stress and associated with increased neutrophil telomere length — plausible immune cell benefit.

PubMed ID: 14652498

Combined supplement (including DHA) attenuated exercise‑driven IL‑6 and CRP increases (immune/inflammatory markers).

PubMed ID: 25268838

Shifted neutrophil eicosanoids toward EPA-derived (less inflammatory) mediators preoperatively.

PubMed ID: 25204316

Omega‑3 reduced LPS‑stimulated PBMC chemokine (RANTES, MCP‑1) expression in dialysis patients (cellular immune modulation).

PubMed ID: 24643636

Omega‑3 decreased depressive symptoms and was associated with modest favorable shifts in inflammatory markers (CRP, ferritin, IL‑10/IL‑6 ratio).

PubMed ID: 24626819

Prenatal DHA reduced some infant respiratory symptoms (subgroup of atopic mothers), suggesting immune/respiratory benefit.

PubMed ID: 24641624

PBMC gene‑expression changes after fish oil indicate immune‑cell modulation.

PubMed ID: 24655407

Perioperative omega‑3 reduced postoperative infections and blunted IL‑6/TNF rise.

PubMed ID: 25307169

DHA‑rich supplement in horses reduced airway neutrophils and clinical cough.

PubMed ID: 25733652

DHA+EPA reduced days ill and prevented iron-associated increases in respiratory illness in children (clinical immune outcome).

PubMed ID: 26074314

PBMC gene‑expression changes by EPA/DHA indicate immune‑modulating (anti‑inflammatory) effects.

PubMed ID: 26340264

Supplementation in obese pregnant women lowered tissue inflammatory markers and systemic CRP (reduced inflammatory state).

PubMed ID: 25976467

Sickle‑cell children showed higher DHA/EPA and reductions in NF‑κB and adhesion markers (immune/inflammatory improvement).

PubMed ID: 26407095

Krill oil raised omega‑3 index and increased NK cell cytotoxicity and PBMC IL‑2 after exercise (direct immune biomarker changes).

PubMed ID: 27394149

Perioperative neonatal DHA lowered proinflammatory cytokines and was linked to fewer infections (immune/clinical outcomes).

PubMed ID: 27187447

Fish oil + flavonoid increased EPA/DHA and upregulated antiviral/interferon gene expression in blood.

PubMed ID: 30311214

Longitudinal neuroimaging showed durable functional/structural brain differences linked to early DHA.

PubMed ID: 27747986

Infant LCPUFA exposure produced electrophysiological differences linked to attention/inhibition, relevant to memory networks.

PubMed ID: 27571269

Infant formula DHA/ARA raised brain‑relevant phospholipids—supports neurodevelopment and memory substrate.

PubMed ID: 25891115

Low-dose DHA/EPA/ARA shortened P300 latency (objective cognitive processing improvement) in older men.

PubMed ID: 24958525

RCT in 6–12 y with ADHD: EPA+DHA increased blood DHA/EPA and produced a selective, statistically significant improvement in working memory.

PubMed ID: 23803884

Follow‑up of infant LCPUFA RCT: later improvements on specific cognitive and language measures between ages 3–6, relevant to memory/cognition.

PubMed ID: 19201180

Schoolchildren consuming fish spread had higher blood DHA/EPA and large, significant improvements in verbal memory measures.

PubMed ID: 19765006

Pooled RCTs in infants found improved means‑end problem solving with formula LCPUFA (including DHA).

PubMed ID: 18519483

Very preterm infants supplemented with DHA+ARA showed better problem‑solving and ERP recognition memory markers at 6 months.

PubMed ID: 15812447

Preterm formula with DHA+ARA improved Bayley developmental scores—supports early cognitive development.

PubMed ID: 15069395

Preterm infants given LCPUFA showed improved Bayley cognitive scores (noted especially in boys).

PubMed ID: 11483801

Preterm AA+DHA improved some motor/development indices though Bayley mental index unchanged; some cognitive benefit signals.

PubMed ID: 10755457

Infants receiving DHA+AA scored ~7 points higher on Bayley MDI at 18 months (cognitive/memory proxy).

PubMed ID: 29458842

24‑week fish oil reduced self‑reported everyday cognitive difficulties and raised RBC EPA+DHA — randomized trial in older adults with subjective complaints.

PubMed ID: 24475144

Souvenaid (contains DHA) preserved EEG network measures in mild AD, supporting memory-related brain network benefit.

PubMed ID: 34113957

EPA‑rich supplementation improved cognitive accuracy and memory accuracy in healthy young adults; DHA effects smaller.

PubMed ID: 33675344

High‑dose EPA+DHA in older adults with coronary disease improved multiple cognitive domains including memory over 12–30 months.

PubMed ID: 34999335

24‑month randomized trial with fish oil + carotenoids showed improved working memory and corresponding biomarker rises.

PubMed ID: 31991898

High‑dose ω‑3/ω‑6+antioxidant over 6 months improved global cognition in older adults with MCI (large effect sizes reported).

PubMed ID: 32856190

MCI patients improved cognitive test scores after DHA and/or folic acid, with combination most effective—direct memory/cognition benefit.

PubMed ID: 30958356

Omega‑3 improved cognition/CDR‑sob in Alzheimer's patients with lower baseline homocysteine (effect modification by B‑vitamin status).

PubMed ID: 21929835

DHA improved a verbal fluency test in older adults with MCI (small RCT) — domain-specific memory/lexical access benefit.

PubMed ID: 20434961

900 mg/day DHA for 24 weeks improved specific learning and verbal recognition memory tests in older adults (RCT with correlated plasma DHA increases).

PubMed ID: 18510807

DHA (±lutein) improved verbal fluency and some memory measures in older women (small RCT).

PubMed ID: 31616139

Prodromal AD trial of Fortasyn Connect (with DHA) slowed clinical decline and hippocampal atrophy though primary NTB cognitive endpoint was negative.

PubMed ID: 27767993

Meta/pooled analyses of Souvenaid (contains DHA) in mild AD show modest but measurable memory-domain improvements (small effect sizes).

PubMed ID: 40044083

12-month RCT in older adults with MCI: DHA (and MCT) improved global cognition vs placebo (combined treatment best).

PubMed ID: 37447152

EPA/DHA + lutein/zeaxanthin produced clinically meaningful episodic memory improvement in older adults with baseline cognitive decline (randomized trials combined).

PubMed ID: 38061271

ARA+DHA improved white matter maturation on MRI in very preterm infants—mechanistic support for later cognitive/memory development.

PubMed ID: 32737350

Older adults: fish‑oil + exercise modestly improved attention and working memory.

PubMed ID: 33396458

Higher maternal AA/DHA at birth predicted faster child information processing to age 9 (observational link to cognitive speed).

PubMed ID: 31345172

Nutrient mix including DHA slowed cognitive worsening in prodromal AD and was linked to reduced dementia risk via preserved cognition.

PubMed ID: 29881917

Fortified milk with DHA increased serum DHA and improved one working‑memory test, supporting a moderate link to memory.

PubMed ID: 29530020

School lunch fatty‑fish RCT produced small, compliance‑dependent improvements in processing speed and fine motor tasks in children (memory/processing domain relevance).

PubMed ID: 29142143

Large 24‑month RCT in MCI: DHA 2 g/day improved multiple cognitive measures (IQ, verbal IQ, digit span) and favorable Aβ/autophagy biomarkers.

PubMed ID: 29097166

Multinutrient drink containing DHA slowed hippocampal atrophy and clinical decline in prodromal AD (memory‑relevant structural/clinical signals).

PubMed ID: 28075381

EPA+DHA for 6 months improved cognitive domains in MCI subjects (direct memory/cognitive benefit).

PubMed ID: 27716665

12‑month 2 g/day DHA in MCI improved several cognitive tests and slowed hippocampal atrophy (robust RCT evidence).

PubMed ID: 26890759

6 months high‑dose omega‑3 raised omega‑3 index and improved spatial (object‑location) memory in healthy older adults.

PubMed ID: 32116250

DHA supplementation increased plasma DHA/AA and higher DHA/AA associated with less hippocampal atrophy (biological substrate for memory).

PubMed ID: 26757190

Higher baseline DHA/EPA potentiated B‑vitamin effects on episodic memory in MCI—strong interaction evidence linking DHA status to memory outcomes.

PubMed ID: 27358067

Oral DHA substantially raised plasma and CSF DHA—supports brain DHA availability relevant to memory.

PubMed ID: 25877495

B‑vitamin effect on brain atrophy in MCI was present only when baseline EPA+DHA was high, implicating omega‑3 status for brain/ memory preservation.

PubMed ID: 24577097

Open-label phosphatidylserine + DHA study showed small improvements in attention and memory in elderly with complaints.

PubMed ID: 24508294

Omega-3 improved several cognitive and attention-related functions in malnourished school-age children (memory-related domains improved).

PubMed ID: 24410954

In mild Alzheimer’s, oral DHA/EPA raised CSF DHA and CSF DHA changes correlated with AD biomarkers relevant to memory/degeneration.

PubMed ID: 23515006

Randomized trial in low‑DHA young adults: 1.16 g/day DHA for 6 months produced statistically significant improvements in episodic and working memory reaction times (robust cognitive benefit).

PubMed ID: 22234041

Cancer patients given n‑3 containing supplement had improvements in cognitive function domains (EORTC cognitive subscale), supporting memory/ cognition benefit in that setting.

PubMed ID: 22932777

12‑month concentrated DHA in MCI improved multiple memory measures vs placebo (small RCT with positive memory outcomes).

PubMed ID: 38244783

In first‑diagnosed, drug‑naïve depressed adults, add‑on EPA+DHA produced a small but significant improvement in immediate memory vs placebo.

PubMed ID: 38952108

12‑month RCT in older adults (800 mg DHA) showed small but significant cognitive (IQ) improvements and oxidative damage reduction.

PubMed ID: 37294565

High‑dose neonatal DHA increased average full‑scale IQ by ≈3.5 points in extremely preterm infants — direct cognitive benefit.

PubMed ID: 35704085

Post‑hoc finding that higher baseline plasma DHA predicted greater cognitive benefit from B‑vitamins, suggesting DHA status supports memory outcomes.

PubMed ID: 34543890

Prenatal DHA improved specific 5‑year cognitive domains (memory and quantitative) in offspring of mothers with a specific FADS2 genotype.

PubMed ID: 33749643

Folic acid + DHA improved arithmetic and digit‑span and lowered blood Aβ in older adults with MCI → support for memory/working memory.

PubMed ID: 20708391

Acute modulation of platelet aggregation by EPA/DHA (sex‑specific) affects haemostatic/circulatory parameters.

PubMed ID: 18982439

Improvements in arrhythmia markers and electrophysiologic indices in cardiomyopathy imply improved cardiac electrical circulation.

PubMed ID: 18339222

Improved heart‑rate variability and lower heart rates indicate better autonomic/vascular function.

PubMed ID: 17875549

Improved endothelial function (FMD) in lupus patients supports improved vascular health.

PubMed ID: 15213026

EPA/DHA markedly increased TRL margination (postprandial margination volume), a physiologic effect on lipoprotein handling at the endothelial surface.

PubMed ID: 14553835

Tuna oil supplementation improved endothelium-dependent vasodilation in healthy middle-aged adults; effect correlated with tissue n-3 rises.

PubMed ID: 12075272

Lower restenosis rates after angioplasty indicate improved vascular outcomes/circulation.

PubMed ID: 12562865

Supplementation accelerated chylomicron TG clearance and raised LPL activity—meaningful improvements in postprandial lipoprotein handling/circulation.

PubMed ID: 10189324

Slowed atherosclerotic progression suggests improved vascular health/circulation over time (modest effect).

PubMed ID: 9665096

Improved left-ventricular diastolic filling (cardiac filling/circulatory function).

PubMed ID: 7486485

Lowered systolic BP and TGs in hypertensive adults can improve vascular health and circulation.

PubMed ID: 1537131

Reduced restenosis after angioplasty indicates improved vascular outcomes/circulation.

PubMed ID: 2240382

Fish oil improved red cell deformability and lipids (physiologic circulation markers) though no walking-distance benefit in claudication.

PubMed ID: 2141757

Dose‑dependent EPA/DHA incorporation with clear TG lowering — improves blood lipid milieu relevant to circulation.

PubMed ID: 12482554

DHA reduced collagen‑stimulated platelet aggregation and TXB2 in hypertensive diabetics, indicating antithrombotic circulation benefits.

PubMed ID: 27903997

Hemodialysis patients on omega‑3 had lower VCAM and higher HDL — favorable vascular/inflammatory changes relevant to circulation.

PubMed ID: 19939650

Children consuming milk fortified with fish oil showed lower endothelial activation markers (E‑selectin, ICAM‑1) — supportive of improved endothelial function/circulation.

PubMed ID: 33041091

Significant increase in nitric oxide and favorable lipid changes after ω‑3 therapy in AMI patients indicate improved endothelial function/circulation.

PubMed ID: 27919362

OM3‑CA altered apoCIII and LDL subspecies—plausible beneficial effects on vascular risk and circulation.

PubMed ID: 21701167

Omega‑3 reduced platelet aggregation and activation markers in CAD patients, consistent with improved hemostatic/circulatory function.

PubMed ID: 15159226

Decreased plasma TAG and platelet AA with increased platelet EPA/DHA suggest improved blood lipid profile and platelet function relevant to circulation.

PubMed ID: 12145002

EPA and DHA markedly increased systemic arterial compliance (+27–36%) in dyslipidemic adults, indicating improved vascular function.

PubMed ID: 1328817

Fish oil lowered triglycerides and reduced platelet aggregation/thromboxane in vascular disease patients — direct circulation/thrombosis relevant effects.

PubMed ID: 37681568

Coronary fatty plaque regression and fewer events imply improved coronary patency/circulatory outcomes.

PubMed ID: 29633621

Three omega‑3 enriched eggs/day improved small‑vessel blood flow (postocclusive reactive hyperemia), and lowered BP and triglycerides in healthy adults.

PubMed ID: 10655965

Dietary EPA/DHA reduced ex vivo platelet aggregation in elderly volunteers—functional evidence for improved hemodynamic/thrombotic profile.

PubMed ID: 22120130

Marked reduction in AF recurrence after EPA+DHA suggests improved cardiac rhythm stability and downstream circulatory benefit.

PubMed ID: 10982541

DHA improved endothelium‑dependent and independent vasodilation and attenuated norepinephrine‑induced vasoconstriction—strong circulatory physiology evidence.

PubMed ID: 38830807

Marked triglyceride and atherogenic lipid reductions are relevant to long‑term vascular health and circulation.

PubMed ID: 38256336

High‑dose EPA+DHA improved ankle‑brachial index (ABI) in dialysis patients — direct evidence of better peripheral circulation.

PubMed ID: 33840228

Higher long‑chain ω‑3s associated with lower cardiovascular/sudden cardiac death in ACS — clinically relevant for circulation outcomes.

PubMed ID: 36050695

Substantial TG and non‑HDL reductions and decreased small dense LDL may improve vascular health and microcirculation.

PubMed ID: 31658051

IV omega‑3 in surgery patients reduced erythrocyte aggregation (and aggregation index) — plausible improvement in microcirculatory flow.

PubMed ID: 32732154

Omega‑3 improved pulse‑wave velocity (arterial stiffness) in CKD patients—direct vascular/circulatory benefit.

PubMed ID: 31076942

Concentrated fish oil reduced platelet aggregation in rheumatoid arthritis patients, suggesting antithrombotic/ circulation benefit.

PubMed ID: 31055222

Higher omega‑3 index associated with less coronary plaque progression — relevant to arterial circulation health.

PubMed ID: 28778393

High‑dose EPA/DHA in PAD patients increased omega‑3 index and pro‑resolving precursors—supports vascular/flow improvements biochemically.

PubMed ID: 28527220

Cross‑sectional study: higher erythrocyte EPA+DHA modestly associated with greater regional brain perfusion on SPECT imaging.

PubMed ID: 26229448

Supplement reduced plaque lipid/cholesterol and perioperative neurologic events—implies improved vascular plaque stability and perioperative circulation.

PubMed ID: 25565485

Lowered central aortic pressures indicate improved central arterial function/circulation.

PubMed ID: 24746829

Dose‑related increase in small‑artery reactive hyperemia index indicates improved microvascular endothelial function.

PubMed ID: 25431880

Increased HRV and lower heart rate suggest improved autonomic cardiovascular regulation and circulation.

PubMed ID: 24997005

Modest lowering of clotting factors and vWF suggests improved hemorheology and reduced thrombotic tendency.

PubMed ID: 23916928

Marked reduction in post-op atrial fibrillation and increased tissue antioxidant enzymes after n‑3 + vitamins—benefit for cardiac rhythm/circulatory outcomes (confounded).

PubMed ID: 23390192

DHA and EPA significantly lowered platelet aggregation compared with placebo, a direct mechanism improving blood flow and reducing thrombosis risk.

PubMed ID: 23238663

Fish oil reduced platelet oxidative stress and PMA-stimulated ROS in hypertensive/diabetic patients—improvements relevant to vascular/platelet function.

PubMed ID: 21831993

Acute postprandial study: inclusion of DHA‑rich oil markedly improved flow‑mediated dilation (+2.06%), a direct and clinically meaningful vascular effect.

PubMed ID: 20071644

Attenuated post-meal decline in conduit artery FMD and improved microvascular reactive hyperemia — strong circulation evidence.

PubMed ID: 16240844

Dietary program raised DHA (~25%) and lowered an oxidative stress marker in postmenopausal women—biochemical/oxidative stress benefit relevant to aging.

PubMed ID: 9310278

Large secondary prevention RCT: fish oil reduced cardiac events and cardiac deaths, which is relevant to healthy aging/end-of-life cardiovascular risk.

PubMed ID: 35171190

Elderly trial showed modest cognitive improvement and higher BDNF with strategies that raised RBC DHA — supports aspects of healthy cognitive aging.

PubMed ID: 19595382

3‑year n‑3 intervention in older men reduced IL‑18 (~10%), a modest anti‑inflammatory change relevant to ageing/inflammaging.

PubMed ID: 27007392

n‑3 in CKD reduced oxidative stress and increased neutrophil telomere length (corrected) — plausible marker of healthy cellular aging.

PubMed ID: 38097963

Functional improvements (handgrip, gait speed) in older CKD patients given a supplement containing EPA/DHA suggest a contribution to healthy aging/function.

PubMed ID: 37447152

DHA/EPA + lutein improved episodic memory in at‑risk older adults, supporting a role in healthy cognitive aging in selected groups.

PubMed ID: 32737350

Older adults: small cognitive gains and DHA increase—relevant to healthy cognitive aging.

PubMed ID: 32116250

Smaller hippocampal atrophy associated with higher DHA/AA after long‑term DHA supplementation suggests neuroprotective effects relevant to aging.

PubMed ID: 23299384

Postmenopausal women randomized to EPA/DHA showed RBC DHA increase and a modest but significant improvement in walking speed over 6 months.

PubMed ID: 22669332

Lovaza in high‑risk postmenopausal women raised n‑3 levels and improved triglycerides/HDL — favorable cardiometabolic signals for healthy aging.

PubMed ID: 24342530

Omega‑3 (DHA/EPA) groups showed smaller telomere shortening in MCI elders—biomarker supporting slowed cellular aging.

PubMed ID: 16983146

Higher plasma DHA associated with less coronary atherosclerosis progression in postmenopausal women—supports aspects of healthy cardiovascular aging.

PubMed ID: 40644954

In older adults, combined n‑3+micronutrients improved n‑3 status and modestly reduced an inflammation composite — relevant to healthy aging.

PubMed ID: 38952108

DHA (with folic acid) improved cognition and reduced DNA oxidative damage / increased mtDNA in older adults — markers relevant to healthy aging.

PubMed ID: 39088212

Three‑year EPA+DHA reduced white‑matter microstructural decline in APOE4 carriers, suggesting a possible aging‑related brain preservation effect in a subgroup.

PubMed ID: 36571774

Six months of fish‑oil improved muscle mass, strength and mobility in older adults—clear functional healthy‑aging benefit.

PubMed ID: 34982486

Post‑MI older adults with larger EPA increases had fewer major CV events (but higher AF risk) — mixed implications for healthy aging.

PubMed ID: 33759678

6‑month multi‑ingredient supplement supplying 3 g EPA+DHA preserved grip strength and improved SPPB in older adults (functional aging outcome).

PubMed ID: 33675344

EPA+DHA improved cognitive domains in older adults with coronary disease — relevant to aging brain health.

PubMed ID: 31991898

MCI older adults had improved cognition, functional capacity and reduced fatigue with ω‑3/ω‑6+antioxidant supplementation.

PubMed ID: 31345172

Nutrient mix including DHA slowed cognitive decline in prodromal AD, a domain of healthy brain aging.

PubMed ID: 29142143

DHA improved cognition and biomarkers in older adults with MCI—relevant to cognitive aspects of healthy aging.

PubMed ID: 29097166

Slower clinical decline and reduced hippocampal atrophy in prodromal AD supports a healthy‑aging/disease‑modifying signal.

PubMed ID: 28075381

Cognitive improvements and reduced inflammatory markers in older adults with MCI support aspects of healthy brain aging.

PubMed ID: 27716665

DHA preserved hippocampal volume and improved cognition in MCI over 12 months—supports neuroprotective aspects of healthy aging.

PubMed ID: 28024882

DHA‑enriched fish oil altered PBMC telomerase and P16 (cell‑senescence biomarkers) in T2D patients, indicating potential aging‑related cellular effects.

PubMed ID: 27033026

Omega‑3 + vitamin E increased SIRT1/PGC1α expression and total antioxidant capacity—molecular markers linked to mitochondrial function/healthy aging, though combined supplement confounds DHA-specific attribution.

PubMed ID: 25877495

Interaction showing omega‑3 status modifies B‑vitamin effect on brain atrophy (relevance to age‑related brain preservation).

PubMed ID: 24453077

Higher RBC EPA+DHA associated with slightly larger total brain and hippocampal volumes in postmenopausal women (observational).

PubMed ID: 24410954

CSF and plasma n‑3 increases in mild Alzheimer’s and correlations with AD biomarkers suggest relevance to neurodegenerative aging processes.

PubMed ID: 21929835

Small randomized trial in older adults with MCI found significant improvements in depressive symptoms with both EPA and DHA vs control.

PubMed ID: 21318452

Six-month low-dose fish oil modestly improved depressive symptoms in elderly in a double-blind RCT.

PubMed ID: 28157380

Youth with mood disorders had large increases in EPA (and DHA) after supplementation; clinical mood benefits were inconsistent but biochemical support is strong.

PubMed ID: 37892462

Perilla oil (ALA) supplementation in pregnancy associated with lower elevated postpartum EPDS scores and erythrocyte ALA predicted lower odds of postpartum distress.

PubMed ID: 15741051

Three months of fish-oil reduced physical aggression and impulsivity in girls (behavioral/mood-relevant outcome).

PubMed ID: 31269506

RCT in major depression found higher remission rates with EPA±DHA vs DHA, and biochemical mediator (EPEA) linked to improvement — relevant to mood regulation.

PubMed ID: 33444934

Adjunctive fish oil with antipsychotic reduced hostility and improved social cognition in psychosis—evidence for mood/social domain benefits in a small RCT.

PubMed ID: 26333890

EPA+DHA attenuated thalamic GSH rise associated with worsening depressive symptoms — signal for mood‑related biology.

PubMed ID: 32977404

Curcumin/fish oil study: increased vigour and reduced total mood disturbance in some subgroups.

PubMed ID: 8613538

Small DB trial in students under academic stress: DHA prevented an increase in outward aggression (mood/behavioral regulation effect).

PubMed ID: 10419086

DHA associated with smaller exam-related aggression increases and altered catecholamine ratios suggesting behavioral/stress modulation.

PubMed ID: 17267927

Omega‑3 improved depression, suicidality and perceived stress in recurrent self‑harm patients (RCT).

PubMed ID: 18539007

Small dose‑finding trial found antidepressant responses at lower DHA doses, suggesting possible mood benefit in some patients.

PubMed ID: 20595646

EPA+DHA for 8 weeks improved depressive symptoms and quality of life in depressed elderly women (double‑blind RCT with clinical effect).

PubMed ID: 22234041

QoL improvements (including cognitive and global health domains) in NSCLC patients may reflect better mood/psychological well‑being.

PubMed ID: 22198441

RCT augmentation: omega-3 added to citalopram significantly improved depressive symptoms and remission rates in MDD.

PubMed ID: 23625531

Randomized study in healthy young men: DHA reduced laboratory measures of aggression and impulsivity, supporting an effect on mood/behavior regulation.

PubMed ID: 24602409

EPA (not DHA) substantially reduced incidence and delayed onset of IFN-α–induced depression in RCT—strong mood signal for EPA arm.

PubMed ID: 24987942

Omega-3 reduced depression scores and improved QoL in hemodialysis patients (RCT, small N).

PubMed ID: 24643636

Randomized trial in hemodialysis patients showed clear reductions in depressive symptoms with omega‑3 supplementation.

PubMed ID: 25431880

Regular salmon intake reduced state‑anxiety in forensic inpatients (mood benefit in dietary trial).

PubMed ID: 25824637

In Korean major‑depression patients EPA+DHA improved clinician‑rated global improvement (signal for mood benefit).

PubMed ID: 26010860

Lower baseline DHA associated with poorer response to antidepressant (paroxetine) in depressed patients—observational association linking DHA status with mood treatment outcomes.

PubMed ID: 26679763

Adjunct n‑3 PUFA in first‑episode schizophrenia improved overall and depressive symptoms (clinically meaningful mood effects).

PubMed ID: 29331711

EPA+DHA modestly reduced self‑reported physical aggression in healthy adults (behavioral/mood effect).

PubMed ID: 29779816

12‑week RCT in obese women with depression: omega‑3 modestly improved depressive symptoms versus placebo.

PubMed ID: 30744880

DHA (±vitamin D) reduced irritability scores in children with ASD in a randomized trial.

PubMed ID: 31641729

In older adults, increases in RBC DHA+EPA over 12 months associated with lower psychotropic/antidepressant use (associative evidence).

PubMed ID: 30776476

Pregnant women with antenatal depression: rising EPA (with estradiol) linked to symptom improvement in omega‑3 group.

PubMed ID: 32179212

Randomized trial in depressed children/adolescents showed clinically meaningful reduction in depressive symptoms with fish oil—strong support for mood benefit.

PubMed ID: 34214231

Adolescent fish‑oil RCT changed emotion‑related functional connectivity and connectivity changes correlated with symptom improvement (robust mechanistic/mood evidence).

PubMed ID: 34139404

In depressed high‑risk youth, fish‑oil raised erythrocyte omega‑3, improved brain network efficiency and produced small additional clinical symptom benefit.

PubMed ID: 36005883

4 g/day EPA increased clinical antidepressant response in inflamed depressed adults (strongest mood signal in dataset).

PubMed ID: 37301235

Small double‑blind RCT in CVD+depression showed earlier fatigue relief and somatic symptom improvement correlated with rising EPA.

PubMed ID: 36635595

High‑dose EPA (4 g/d) increased responder rates in adults with MDD and inflammation — direct antidepressant/mood signal.

PubMed ID: 39519521

Small RCT: high‑dose omega‑3 (~3.2 g/day) reduced clinician‑rated depressive symptoms versus placebo.

PubMed ID: 39306009

52‑week EPA+DHA markedly reduced recurrence risk of depression in euthymic older adults (large HR effect), supporting mood‑stabilizing benefit.

PubMed ID: 20624152

VLBW infants supplemented with DHA+ARA showed improved sustained attention at 20 months (robust behavioral finding).

PubMed ID: 19201180

Schoolchildren had cognitive gains (verbal memory, spelling) after fish‑spread intake—improvements consistent with better attention/focus.

PubMed ID: 18586645

DHA‑rich fish oil in children increased RBC DHA and was associated with better school attendance (functional benefit).

PubMed ID: 22753087

In ADHD children, omega-3/6 supplementation changed plasma n-3 and responders had larger n-3 increases; clinical symptom improvement tied to attention-focused endpoints.

PubMed ID: 18469236

Randomized trial in inattentive children: EPA/DHA (esp. phospholipid form) improved sustained attention (TOVA).

PubMed ID: 32737350

Exercise + fish‑oil improved attention in older adults with low muscle mass.

PubMed ID: 33396458

Maternal AA/DHA at birth predicted faster information processing (processing speed) to age 9—supports focused cognitive processing links.

PubMed ID: 30311214

Long‑term neuroimaging showed stronger attention network connectivity with early LCPUFA exposure.

PubMed ID: 27747986

Infant LCPUFA led to stronger ERP attention/inhibition signals and faster responding tendency.

PubMed ID: 24958525

Working memory improvements in ADHD children (erythrocyte EPA/DHA rises) support enhanced cognitive control and focus.

PubMed ID: 23783296

Infant LC‑PUFA supplementation produced faster processing speed at age 6, a domain related to sustained attention/focus.

PubMed ID: 20130094

Dose‑dependent increases in erythrocyte DHA in boys accompanied by increased dorsolateral prefrontal activation during sustained attention and faster reaction times (fMRI + behavioral evidence).

PubMed ID: 22020134

DHA-rich fish oil increased prefrontal oxyhemoglobin during cognitive tasks in young adults—physiologic correlate compatible with improved focus despite little performance change.

PubMed ID: 22970149

600 mg/day DHA for 16 weeks reduced parent‑rated ADHD behaviors and produced small reading gains in poorest readers, consistent with improved attention/behavior in subsets.

PubMed ID: 22234041

Cognitive domain improvements in cancer patients (cognitive function subscale) indicate better focus/mental function in that clinical setting.

PubMed ID: 24568073

In ADHD children, EPA+DHA improved hyperactivity and decreased inflammatory markers—behavioral gains relevant to attention/focus.

PubMed ID: 24214970

RBC EPA+DHA levels correlated with better attention, behavior and spelling in children with ADHD (within-subject associations).

PubMed ID: 23515006

DHA supplementation improved reaction time on episodic and working memory tasks in young adults—consistent with improved processing speed/attention.

PubMed ID: 24508294

Omega-3 supplementation improved processing speed, attention and executive function in malnourished school-age children (RCT).

PubMed ID: 24577097

PS enriched with DHA associated with small improvements in sustained attention in elderly with complaints (open-label).

PubMed ID: 25790022

Randomized trial showed reduced parent‑rated inattention in boys and increased cheek‑cell DHA (direct focus/attention benefit).

PubMed ID: 27362506

Prenatal DHA (600 mg/day) produced more stable sustained attention from 4 to 9 months and faster habituation—direct evidence for early attention/focus benefits.

PubMed ID: 27604770

Large prenatal DHA RCT produced improved sustained attention at age 5 (direct evidence for improved focus).

PubMed ID: 28075381

Improvements in perceptual speed, working memory and other cognitive domains in MCI are relevant to attention/focus.

PubMed ID: 31991898

Global cognition improved in older adults with MCI, which can include attention and focus domains.

PubMed ID: 32529206

Oily fish consumption in 8–9‑year‑olds improved attention errors and reaction time—evidence for improved focus in children.

PubMed ID: 34113957

EPA‑rich supplementation improved global accuracy and speed in cognitive testing of healthy young adults — supports attentional/processing benefits.

PubMed ID: 33749643

Digit‑span (working memory) and arithmetic improved with folic acid + DHA in MCI subjects — supports attention/working memory (focus).

PubMed ID: 34139404

Fish‑oil improved brain network efficiency in depressed youth, plausibly aiding cognitive processing and focus.

PubMed ID: 35704085

Higher plasma DHA predicted greater cognitive benefit from B‑vitamins over 2 years—suggests DHA status supports cognitive domains including attention/focus.

PubMed ID: 37294565

Preterm neonatal DHA increased IQ which may reflect broad cognitive/attentional gains in early development.

PubMed ID: 40791013

Higher prenatal DHA (800 mg) was associated with faster infant visual learning and more mature attention patterns — direct early‑life focus/attention signal.

PubMed ID: 19765006

Infant LCPUFA supplementation improved problem solving and intentionality scores—supports early executive/attentional development.

PubMed ID: 34371972

In overweight postmenopausal women, DHA‑rich supplements modestly reduced diastolic blood pressure when combined with resistance training.

PubMed ID: 32963294

DHA‑enriched foods reduced 24‑h ambulatory diastolic blood pressure (~3.1 mmHg) and heart rate—direct BP benefit.

PubMed ID: 30735073

DHA lowered resting systolic and diastolic BP by ~3.4 mmHg vs EPA in randomized healthy‑adult trial.

PubMed ID: 30794304

Prenatal DHA (600 mg/day) associated with ~4–5 mmHg lower SBP/DBP at 4–6 y in offspring who became overweight/obese.

PubMed ID: 26817716

Low-to-moderate fish oil intakes lowered systolic BP by ~5 mmHg in adults with isolated systolic hypertension (subgroup), a clinically meaningful blood-pressure effect in that group.

PubMed ID: 25565485

High‑dose fish oil arm showed significant decreases in aortic pulse pressure and augmentation pressure (central BP improvements).

PubMed ID: 24401815

Large randomized trial found fish‑oil lowered BP in noncarriers of a specific CSK variant (gene × treatment interaction), indicating BP benefit in a genetic subgroup.

PubMed ID: 24829493

DHA‑enriched oil lowered systolic blood pressure (~3.3%) in a controlled trial—direct BP effect.

PubMed ID: 23104856

Small trial found a clinically meaningful systolic BP reduction (≈6.8 mmHg) and pulse pressure drop after 6 weeks of fish oil.

PubMed ID: 20472253

Adolescents showed significant SBP (−3.8 mmHg) and DBP (−2.6 mmHg) reductions — clear BP benefit.

PubMed ID: 19487105

During energy restriction, salmon or fish oil modestly lowered diastolic blood pressure (~2.5 mmHg vs control) in overweight young adults (randomized dietary trial).

PubMed ID: 19593941

6‑month fish‑oil in metabolic syndrome lowered systolic blood pressure (P<0.05) alongside other cardiometabolic improvements.

PubMed ID: 18665413

Lean fish four times/week modestly lowered systolic and diastolic BP in CHD patients (randomized dietary intervention with BP changes).

PubMed ID: 17374663

Low‑dose DHA produced a statistically significant −3.3 mm Hg reduction in diastolic blood pressure in middle‑aged adults.

PubMed ID: 11207085

Omega-3 prevented systolic BP rise and systemic vascular resistance increases in heart-transplant patients (strong BP protection).

PubMed ID: 10454450

Purified DHA significantly reduced 24-hour ambulatory systolic/diastolic BP and heart rate in mildly hyperlipidemic men—strong direct BP benefit.

PubMed ID: 9733153

Moderate-dose EPA+DHA lowered systolic (~6 mmHg) and diastolic (~5 mmHg) BP in mild hypertensives after 2 months—clinically meaningful.

PubMed ID: 7891046

High-EPA/DHA concentrate lowered both systolic and diastolic blood pressure in hyperlipidemic patients.

PubMed ID: 7486485

RCT: 4 g/day EPA+DHA for 16 weeks lowered systolic BP by ~3.8 mmHg vs control (P=0.04) in hypertensive adults.

PubMed ID: 1828336

Small crossover RCT in mild hypertension showed modest but statistically significant systolic/diastolic BP reductions.

PubMed ID: 2137901

Large RCT: high‑dose EPA+DHA produced modest but clinically meaningful systolic/diastolic BP reductions vs corn oil.

PubMed ID: 8729141

Cross‑population comparison found markedly lower systolic BP (~15 mmHg lower) in the lake‑fish (higher DHA) group versus vegetarian community (observational association).

PubMed ID: 29633621

Three omega‑3 enriched eggs/day lowered blood pressure in healthy young adults (study reported BP decrease).

PubMed ID: 30511840

2 g/day fish oil reduced systolic blood pressure (~4.5 mmHg) and decreased plasma angiotensin II in hypertensive adults.

PubMed ID: 1971991

Marine EPA+DHA diet lowered systolic blood pressure by ~5.1 mmHg versus linoleic acid diet in men — direct BP benefit.

PubMed ID: 2147175

Fish oil lowered blood pressure in men with mild hypertension and reduced norepinephrine—direct antihypertensive signal.

PubMed ID: 27552592

Higher EPA increases linked to lower PTSD symptom severity at 12 weeks—evidence for stress/trauma resilience.

PubMed ID: 27287561

Post‑trauma omega‑3 reduced heart‑rate reactivity during traumatic recall—strong physiological stress resilience signal.

PubMed ID: 27007392

Reduced oxidative stress and increased neutrophil telomere length suggest improved cellular resilience to stressors.

PubMed ID: 8613538

DHA supplementation prevented stress‑related increases in outward aggression in students under academic stress (direct stress‑resilience finding).

PubMed ID: 10419086

DHA intake associated with attenuated exam-related aggression and altered stress-hormone ratios, supporting stress-buffering effects.

PubMed ID: 17267927

Perceived daily stress scores improved in recurrent self‑harm patients on omega‑3 (RCT).

PubMed ID: 18982439

Dilated cardiomyopathy study showed decreased catecholamines and cytokines after n‑3, indicating reduced physiologic stress signaling.

PubMed ID: 21967854

Low‑dose EPA+DHA reduced MAP reactivity to mental stress in healthy volunteers (randomized, short trial) — direct evidence for physiologic stress resilience.

PubMed ID: 24602409

EPA delayed onset of IFN-α–induced depression—supports resilience to treatment-related stressors.

PubMed ID: 25415158

Omega‑3 supplementation in a high‑stress, low‑income pregnant cohort modestly lowered perceived stress and baseline cortisol late in pregnancy.

PubMed ID: 24987942

Reduced depression and improved QoL in dialysis patients suggests better resilience to chronic stressors.

PubMed ID: 24899596

Supplementation reduced cigarette use and cue-induced craving, implying improved stress/urge coping.

PubMed ID: 26010860

Lower DHA was linked to altered fatty‑acid–cortisol relationships and poorer antidepressant response, implicating DHA status in HPA-axis/stress biology.

PubMed ID: 27290652

Prenatal DHA lowered infant cortisol responses to a stressor and improved some neonatal outcomes (direct stress‑reactivity effect).

PubMed ID: 35953431

Higher‑dose prenatal DHA increased vagal HRV measures (marker of autonomic regulation and stress resilience).

PubMed ID: 40347940

Fish oil reduced serum cortisol and improved sleep/circadian markers—physiologic evidence of improved stress response.

PubMed ID: 11237197

DHA supplementation blunted stress‑related hostility and reduced norepinephrine during exam stress—strong stress‑resilience signal.

PubMed ID: 25585167

EPA+DHA reduced transition to psychosis and improved functioning in high‑risk youth—suggests improved resilience to psychotic/stressful progression.

PubMed ID: 26078579

PUFA‑enriched diet in biopsy‑proven NASH improved liver enzymes, lipids and histology—substantial liver disease benefit (includes DHA).

PubMed ID: 26026214

MRI‑based RCT in overweight children reported ~53% relative hepatic fat reduction with DHA—robust liver‑fat improvement.

PubMed ID: 22796064

Parenteral fish‑oil containing emulsion raised EPA/DHA and produced modest improvements in liver enzymes over 4 weeks.

PubMed ID: 23220074

Up to 24‑month follow‑up showed sustained reductions in liver fat and improved triglycerides/ALT with long‑term DHA—strong liver benefit.

PubMed ID: 21233083

Randomized trial in children with NAFLD showed large, significant reductions in liver steatosis and improvements in triglycerides/insulin with DHA.

PubMed ID: 26226139

Adults with NAFLD had improvements in triglycerides and ALT/GGT and reductions in NAFLD biomarkers with fish oil—meaningful liver benefit.

PubMed ID: 38680033

In newborns with hyperbilirubinemia, DHA reduced serum bilirubin, NSE, phototherapy duration and abnormal MRI—strong liver/bilirubin outcome.

PubMed ID: 32188593

EPA+DHA supplementation markedly decreased hepatic de novo lipogenesis and increased postprandial fat oxidation in randomized trial → direct hepatic metabolic benefit.

PubMed ID: 30177465

Fish‑oil containing lipid emulsion reduced parenteral nutrition‑associated cholestasis in very premature infants (clinically meaningful liver benefit).

PubMed ID: 30127297

High‑concentrate EPA+DHA substantially raised RBC ω‑3 and lowered triglycerides with liver‑fat improvements in high‑FLI NAFLD subgroup.

PubMed ID: 26748347

In NAFLD patients, greater DHA tissue enrichment associated with decreased liver fat, linking DHA exposure to hepatic fat reduction.

PubMed ID: 25043514

In NAFLD patients, erythrocyte DHA enrichment was strongly associated with meaningful reductions in liver fat (per‑% DHA effect significant).

PubMed ID: 23963690

In very low birth weight infants parenteral fish‑oil emulsions with DHA markedly reduced cholestasis (large clinical benefit) and raised DHA—strong liver‑protection evidence in neonates.

PubMed ID: 27977757

Children with NAFLD receiving DHA+vitamin D had large histologic and metabolic improvements; DHA likely contributed though combo limits attribution.

PubMed ID: 24074360

Randomized trial in children with NAFLD: DHA supplementation halved the chance of worse liver steatosis vs placebo — strong, clinically meaningful effect.

PubMed ID: 15239141

Randomized trial in postoperative cancer patients showed lower postoperative AST/ALT, bilirubin and better biochemical liver markers with fish-oil nutrition (direct liver benefit).

PubMed ID: 39202647

3‑month methyl‑donor + n‑3 cocktail reduced FibroScan CAP and liver stiffness vs placebo in obese adults — pilot evidence for steatosis/stiffness improvement.

PubMed ID: 26047766

Mixed ALA+marine ω‑3 supplementation in NASH patients improved triglycerides and increases in PUFA correlated with histologic improvement—direct liver relevance.

PubMed ID: 28511023

Multi‑nutrient intervention including DHA produced marked reductions in severe steatosis and ALT in pediatric NASH—positive but multicomponent.

PubMed ID: 32044905

Reduced systemic inflammatory markers (TNF‑α, CRP), a plausible mechanism for improving joint pain/inflammation.

PubMed ID: 29752179

Secondary analysis in CAD patients: 1 year of EPA+DHA associated with preserved physical function and far fewer joint replacements, suggesting joint benefit.

PubMed ID: 19756416

Adding EPA/DHA to glucosamine increased the proportion of osteoarthritis patients with large pain reductions (clinical symptom benefit in combo therapy).

PubMed ID: 8220938

Year‑long RCT in RA showed patients could markedly cut NSAID use without clinical deterioration, indicating meaningful joint/inflammatory benefit.

PubMed ID: 1464864

Omega‑3 supplementation (with naproxen) reduced morning stiffness and improved global assessments in RA, but concomitant NSAID use confounds effect attribution.

PubMed ID: 2363736

Larger randomized trial: dose-dependent reductions in swollen/tender joints and LTB4.

PubMed ID: 37686880

Randomized double‑blind trial: omega‑3 (AvailOm) improved knee pain/function and muscle performance over 8 weeks, supporting joint symptom benefit.

PubMed ID: 35880828

Large 6‑month RCT: krill oil (EPA+DHA) modestly but significantly improved knee pain (WOMAC) versus placebo.

PubMed ID: 29471285

DHA lowered adipose inflammatory genes and hsCRP—plausible mechanism for joint symptom relief.

PubMed ID: 28302406

Randomized crossover in RA patients produced clinically meaningful decreases in tender+swollen joint counts and anti‑inflammatory mediator shifts.

PubMed ID: 20739445

Nutritional formula increased energy and protein intake and preserved weight/FFM in cancer patients — meaningful for energy/functional status.

PubMed ID: 22160495

Fish oil during chemotherapy prevented weight loss and preserved neutrophil function (+1.7 kg vs −2.5 kg), which can translate into better energy/strength during treatment.

PubMed ID: 22234041

n‑3 containing oral supplement during chemoradiotherapy improved physical activity and global/physical function scores, consistent with higher energy/functional capacity.

PubMed ID: 25054452

High‑dose EPA+DHA modestly increased resting metabolic rate and UCP3 (supporting small increases in energy expenditure).

PubMed ID: 26085822

Three weeks of omega‑3 increased plasma EPA and was associated with increased muscle activation and attenuated fatigue measures in male athletes—supports short-term performance/energy effects.

PubMed ID: 29752179

EPA+DHA preserved physical function and increased exercise minutes/week in CAD patients over 1 year—supports sustained energy/functional capacity.

PubMed ID: 33087145

DHA supplementation improved submaximal cycling power at VT2 in trained cyclists—functional increase in exercise capacity/energetics.

PubMed ID: 31991898

Supplementation reduced fatigue and improved functional capacity (6MWT, STS) in older adults with MCI — consistent with increased perceived/functional energy.

PubMed ID: 37301235

Omega‑3 (2 g EPA + 1 g DHA) eased fatigue more quickly in CVD+depression patients (early effect).

PubMed ID: 2270749

Multi‑EFA (including DHA) trial in postviral fatigue showed large self‑reported improvements in energy/fatigue vs placebo.

PubMed ID: 19054188

DHA+EPA supplements modestly increased weight and appetite in mild–moderate AD patients, reflecting improved energy intake/status.

PubMed ID: 22269042

Maternal DHA reduced infant arousals in early postnatal sleep (clear randomized result indicating improved sleep organization).

PubMed ID: 31538590

Large RCT in preterm toddlers showed no overall sleep change but subgroup increases in nocturnal sleep (boys; children of depressed caregivers).

PubMed ID: 24605819

16‑week algal DHA (600 mg/d) in schoolchildren increased objective sleep time by ~58 minutes and reduced night wakings in actigraphy subgroup.

PubMed ID: 36235788

12‑week DHA+EPA RCT in poor sleepers increased sleep efficiency and improved a dream‑related subjective factor with objective blood uptake (strong direct evidence).

PubMed ID: 33467135

Small RCT: DHA supplementation modestly improved objective sleep efficiency and reduced sleep latency in adults with low fish intake.

PubMed ID: 24812543

Regular fatty‑fish intake in winter preserved sleep measures and increased HRV in a randomized dietary study—clinically meaningful for sleep maintenance.

PubMed ID: 40347940

Randomized trial and mechanistic work showed improved PSQI sleep scores, reduced cortisol and upregulated clock genes after fish‑oil.

PubMed ID: 22302614

Pilot RCT in early postmenopausal women: combination (genistein + EPA/DHA + vitamins) helped preserve/increase hip BMD sites — suggests DHA contribution but confounded.

PubMed ID: 20579524

One‑year randomized replacement with fortified milk (including fish oil) raised EPA/DHA and improved bone‑formation markers (osteocalcin +22%) — supportive of bone turnover benefits (multi‑ingredient).

PubMed ID: 24274259

High‑dose EPA+DHA for 3 months in postmenopausal breast cancer survivors on aromatase inhibitors raised serum n‑3 and inhibited bone resorption in responders.

PubMed ID: 9555791

IV omega-3 significantly reduced psoriasis severity (skin disease), which indicates skin benefit though not specifically hydration.